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I am very pleased to see the publication of the new IMPACT Guidelines 
(2012), now into its fourth edition.  The updated IMPACT Guidelines 
combined the latest scientific evidence and local data on the prevalence 
and sensitivity patterns of different pathogens.  I am confident that the 
IMPACT Guidelines will continue to serve as an invaluable reference tool 
for our medical and health professionals in reinforcing the appropriate use 
of antimicrobial drugs. 
 
We are deeply indebted to the Chairman of the IMPACT Editorial Board, 
Professor HO Pak-Leung, for his strong leadership, professional expertise, 
and selfless dedication of his precious time and energy.  My heartfelt 
appreciation also goes to each and every colleague and representative from 
all medical organizations who contributed to the realization of this new 
edition of IMPACT. 
 
Antimicrobial resistance threatens the continued effectiveness of many 
medicines used today to treat the sick.  Moreover, it deters important 
advances being made against major infectious killers, imposing huge costs 
to individuals and society.  The Centre for Health Protection is committed 
to work hand in hand with medical professionals in Hong Kong to address 




Dr. Thomas Ho Fai, TSANG 
Controller 
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The discovery of penicillin by Alexander Fleming in 1928 marked the 
advent of the antibiotic era, and for the following 40 years, more than 20 
structural classes of new antimicrobial agents were discovered and 
brought into clinical use. The spate of Nobel prizes awarded to the early 
pioneers, Waksman, Fleming, Florey, Chain and Domagk, for the 
development of the first effective antimicrobial agents was a clear evidence 
of the great importance attributed to these achievements. 
  
Now into the 21st century, antimicrobial agents are commonly prescribed 
for the purposes of treatment of and prophylaxis against infections, in the 
realms of public health management and travel medicine. At the same time, 
world-wide emergence of antimicrobial resistance and the spread of 
resistant microorganisms are among the major challenges plaguing the 
global community in the healthcare context. 
 
At this moment, smart and rational use of antimicrobial agents is of 
paramount importance in preventing antimicrobial resistance and 
salvaging the market-available antibiotics for a longer life span. Common 
prescribing errors which lead to undesirable clinical outcomes should be 
avoided. These include treatment of colonization, inappropriate empiric 
therapy and combination therapy, suboptimal dosing and duration, and 
mismanagement of apparent antibiotic failure. 
  
Publication of the fourth edition of IMPACT is an opportune moment to 
share constructive comments from clinicians and other colleagues and 
insights on the forthcoming battle against antibiotic resistance. The new 
edition has evolved from the third one by incorporating up-to-date data on 
epidemiology, prevalence of pathogens and their antimicrobial resistance 
profiles while maintaining the art of basic sciences throughout the 
comprehensive review process. I believe the fourth edition of IMPACT would 
provide a good reference for our clinicians in the use of antimicrobial 
agents to achieve maximal clinical benefits.  
  
I would like to thank the many people and organizations who have 
contributed to the successful launching of the fourth edition of IMPACT 
and look forward to your continued support in the appropriate use of 
antibiotics as an effective means to control antimicrobial resistance. 
 
 










Hong Kong is plighted by a multitude of antibiotic-resistant bacteria. As 
bacteria including Staphylococcus aureus, Escherichia coli, Acinetobacter 
baumannii which are causative agents of the major infectious syndromes - 
skin and soft tissue infections, pneumonia, urinary tract infections, 
septicaemia - become increasingly resistant to agents that are widely used 
for their empirical treatment. Clinicians face increasing numbers of “hit and 
miss” situations in the hospital and in the community. While there is clearly 
a need for new antibiotics, pharmaceutical investment in antibiotic research 
has declined in the past decade leading to decreasing number of new 
antibacterial drugs approved for marketing and a dry pipeline for the near 
future. This is why the medical profession must be more critical than ever of 
antibiotic use. 
 
IMPACT recognizes the dangers from antimicrobial resistance, which has 
reached alarming levels, the tremendous adverse effect it has on quality 
medical care and the need for a strong, coordinated and multifaceted 
response. To meet this challenge, the IMPACT editorial board has been 
broadened and all sections of the document have been revised. As in the 
previous editions, the content focuses on the clinical situations in which the 
local epidemiology is unique; highlighting the antimicrobial agents with a 
strong link to development of multidrug-resistant organisms or that dosing 
and monitoring are complicated. Where appropriate, comments by the 
IMPACT group are provided to facilitate a more prudent use of antimicrobial 
agents. Several new sections have been added, including smart use of 
antibiotics in outpatient settings, management of antibiotic allergy and tips 
on laboratory diagnostic tests. To meet the needs of different individuals, 
the publication is available in two hardcopy sizes (pocket and A4), at the 
homepages of the partner organizations and made accessible as an Apps to 
users of mobile phones. 
 
I am grateful to the contributions by our experts in the editorial board. On 
behalf of the IMPACT group, we thank the Centre for Health Protection for 
the generous financial support in printing the hard copies and for 






















Part I: Antibiotic resistance - Local scenario 
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1.1 Background: the problem of antimicrobial resistance 
in Hong Kong 
1. The emergence of resistance has threatened the successful 
treatment of patient with infections [1-5]. 
2. Antimicrobial resistance increases drug costs, length of stay and 
adversely affects patient’s outcome [6]. 
3. Resistance to all classes of antibiotics has developed to various 
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Table 1.2 Intrinsic and associated resistance to antimicrobial 
agents among five nosocomial pathogens 
Bacteria Intrinsic Resistance 
Associated 
Resistance 

























including third  
generation 
cephalosporins, (variable 
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aztreonam is associated 
























































































































Ampicillin + sulbactam 
Amoxicillin + clavulanate 
Piperacillin 
Ticarcillin + clavulanate 
Piperacillin + tazobactam 
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1.2 Methicillin-resistant Staphylococcus aureus 
Due to the alternation of penicillin binding protein, methicillin-
resistant Staphylococcus aureus (MRSA) are resistant to penicillins, 
(including oxacillin, cloxacillin and flucloxacillin), BLBLI, 
cephalosporins, and carbapenems. Only the new anti-MRSA beta-
lactams (e.g. ceftaroline) retain activity against MRSA. 
MRSA has been categorized into healthcare-associated (HA-MRSA) and 
community-associated (CA-MRSA). The Center for Disease Control and 
Prevention (CDC) classification, which is the most widely accepted, 
classified HA-MRSA and CA-MRSA epidemiologically [7]. However the 
border between the two is becoming blurred and surveillance using 
epidemiological criteria alone has become insufficient (Table 1.4). 
 
1.2.1 Healthcare-associated MRSA (HA-MRSA) 
 
1. For S. aureus that are susceptible to methicillin, vancomycin is 
inferior to anti-staphylococcal beta-lactam [8]. However, 
vancomycin remains the treatment of choice for infection caused by 
MRSA. The efficacy of vancomycin may be limited by inadequate 
dosing, poor tissue penetration, slow bactericidal activity and 
strains with reduced susceptibility to the drug [8, 9].  
2. In the recent years, a silent and gradual increase in the vancomycin 
MIC has been observed. This phenomenon is known as ‘vancomycin 
creep’ [10, 11]. Since the increment is small and the MIC still falls 
within the range of ‘sensitive’, it usually goes unnoticed. This 
phenomenon has also been observed in Hong Kong [12]. In HK, 
there has been a gradual increase in the number of strains with 
vancomycin MIC = 1 μg/ml from 1997 to 2008. The elevated MIC 
paralleled an increase in consumption of vancomycin [12].   
3. The vancomycin creep has been observed in some, but not all 
centers. This is probably due to difference in the susceptibility 
testing methods, clonal dissemination of more resistance strain and 
the intensity of vancomycin usage [12].   
4. Vancomycin MIC ≥ 2 μg/ml has been associated with vancomycin 
treatment failure [13-15]. Therefore, guidelines have recommended 
isolates with vancomycin MIC ≥ 2 μg/ml be treated with an 
alternative antibiotic instead of vancomycin [8].  
5. The susceptibility profile cannot be used as a differentiating feature 
of HA-MRSA and CA-MRSA. In a recent local report, it 
demonstrated an increase in prevalence of multi-susceptible MRSA 
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(MS-MRSA) over the past few years in the hospital setting. The MS-
MRSA represents HA-MRSA and the increase in isolates was 
associated with the spread of the clone ST45 possessing SCCmec 
type IV or V. About 75% of these isolates were recovered from 
elderly living in residential care homes. This represents that these 
strains may be more transmissible among the elderly in residential 
care home and convalescent care settings, serving as a reservoir 
[16]. 
 
1.2.2 Community-associated MRSA (CA-MRSA) 
 
1. CA-MRSA is rapidly emerging in the Hong Kong community [17] 
and reporting to the Department of Health (DH) has been made 
mandatory since January 2007. It is responsible for 10.4% of 
purulent cellulitis and 5% of cutaneous abscess in the A&E setting 
[18]. 
2. During 2009-2011, 2.1% of the 1 487 CA-MRSA cases reported to 
the DH were invasive infections. The mortality of invasive CA-MRSA 
infections was 25%. In HK, serious infections and deaths have 
occurred in otherwise healthy children and adults.  
3. Patient infected with CA-MRSA do not have the usual risk factors 
associated with HA-MRSA. In our locality, ethnic minority, sharing 
of personal items with other persons have been found to be risk 
factors while frequent hand washing was CA-MRSA infection [17, 
19]. 
4. PVL (Panton-Valentine leukocidin) toxin is a pore forming cytotoxin 
that is capable of destroying human monocytes and neutrophils. 
PVL has been associated with virulence and transmissibility of CA-
MRSA. In Hong Kong, 68% of the CA-MRSA causing skin and soft 
tissue infection possesses PVL toxin.  
5. Other than skin and soft tissue infection, PVL toxin is also 
associated with necrotizing pneumonia, necrotizing fasciitis and 
meningitis. CA-MRSA has also been reported to co-infect with 
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Table 1.4 Characteristics of different types of MRSA 










Also seen in SE Asia 
ST45  
(belongs to CC45) 
Found in Community Hospitals & old age 
homes 
Hospitals & old age 
homes 
SCCmec IV or V III / IIIA IV or V 
PVL + (~68%) - - 
Gentamicin S R S 
Erythromycin & 
Clindamycin 
Variable   
Cotrimoxazole S R S 
Fusidic acid S R S 
Minocycline S R  
Clinical 
spectrum 





Necrotizing pneumonia   
Necrotizing fasciitis   
Severe sepsis   
CA-MRSA, community-associated MRSA; HA-MRSA, healthcare-associated MRSA; 
MS-MRSA, multisusceptible MRSA. 
 
 
1.3 Vancomycin-resistant enterococci 
 
1. Vancomycin-resistant Enterococcus faecalis (VREfs) and E. faecium 
(VREfm) were first reported in Europe in 1986. Since then, VRE 
have spread throughout the world and have become a major 
nosocomial pathogen. In the United States and some European 
countries, VRE (especially VREfm) have disseminated widely in the 
hospitals and old age homes [23].  
2. In Hong Kong, the first case of VREfm was identified in 1997 in a 
patient returning from the United States. During 1997-2008, the 
occurrence of VRE was sporadic which on several occasions have 
led to small clusters (<5 to 10 cases) of nosocomial transmission. 
There had been no continued transmission in our healthcare 
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system. Two ad hoc studies demonstrated that VRE was carried by 
<0.1% of patients in high risk areas [24, 25].  
3. Since 2009, the epidemiology of VRE in HK is rapidly evolving. This 
followed the detection of an epidemic strain of VREfm in several 
public hospitals. By January 2012, the epidemic strain was 
disseminated to more than ten public hospitals and affecting over a 
hundred patients and residents of more than ten old age homes. 
This VREfm clone is becoming endemic in some of our public 
hospitals and old age homes. 
4. Vancomycin resistance in enterococcus is plasmid-mediated. The 
vanA gene is encoded in a transposon Tn1546 and vanB encoded in 
Tn1547. The transposons are mobile and able to disseminate the 
resistant gene to other more virulent organisms, e.g. Staphylococcus 
aureus. Therefore, despite the low pathogenicity of VRE, they can 
act as a reservoir of mobile resistance gene [26].  
5. Hospital outbreak caused by VRE has been increasing reported 
worldwide. Molecular epidemiology study by MLST revealed that this 
rise is attributed to the spread of a genetic lineage of Enterococcus 
faecium clonal complex-17, CC17, Table 1.5 [26, 27].  CC17 is now 
the predominant clone seen in hospital outbreaks and has been 
reported in the Netherlands [28], Spain [29], Germany [30], South 
America [31]  and Taiwan [32].  
6. Most of the CC17 E. faecium remains susceptible to linezolid. 
However in a Germany survey, selection of linezolid-resistance 
epidemic-virulent CC17 strains of enterococcus occurred during 
Linezolid therapy [30]. It is due to the accumulation of mutations in 
position 2 576 of the 23s rDNA for at least one of the 23S rRNA gene 
copies, necessary for acquisition of phenotypic linezolid resistance 
in E. faecium.  
7. Molecular epidemiological study has shown that CC17 has been 
circulating in hospitals in the United States since early 1980s [26].  
Table 1.5 Characteristics of vancomycin-resistant E. faecium, CC17 
1. Multidrug-resistant, including resistance to: 
a. Ampicillin 
b. Quinolones 
2. Contains a putative pathogenicity island and the esp gene which encodes 
for a protein involved in colonization and biofilm formation 
3. An association with hospital outbreaks 
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1.4 ESBL-positive Enterobacteriaceae 
 
1. ESBLs are enzymes capable of hydrolyzing penicillin, first-, second- 
and third-generation (extended-spectrum) cephalosporins and 
aztreonam (except the cephamycins and carbapenems). Most ESBLs 
can be inhibited by the beta-lactamase inhibitors such as clavulanic 
acid and tazobactam [33]. (Table 1.6.) TEM, SHV and CTX-M are the 
three most common family of ESBL seen worldwide.  
2. In Hong Kong (Figure 1.1), >90% of strains with an ESBL phenotype 
produced the CTX-M type enzymes [34, 35]. There is a high rate of 
resistance towards non-beta-lactam antibiotics, particularly 
quinolones, cotrimoxazole and aminoglycosides [34, 35]. The high 
rate of resistance to non-beta-lactam antibiotics therefore limits the 
choice for management of patients in outpatient setting.  
3. ESBL-positive Enterobacteriaceae has been considered to be a 
hospital pathogen in the past. However, community-onset infection 
has been described in different countries in the recent years. Most 
of the patients presented with lower urinary tract infection, other 
presentation includes bacteraemia and intra-abdominal infection 
[36-39].  
4. Rectal colonization with ESBL-positive Enterobacteriaceae has been 
increasingly seen in healthy individuals [40], and this has been 
postulated to be a risk factor for community-onset ESBL-positive 
Enterobacteriaceae infection. Food animals are a major reservoir of 
ESBL-positive E. coli [41, 42].   
5. For two decades, ESBL-positive Enterobacteriaceae were considered 
to be clinically resistant to all cephalosporins. Accordingly, all 
laboratories are advised to edit the results for ceftazidime, 
ceftriaxone and cefepime to resistant, irrespective of the in vitro 
inhibition zone diameters or MIC values.  
6. Recently, the laboratory testing advisory bodies in the US (CLSI) and 
Europe (EUCAST) have revised their advice and argued that with 
the lowered cephalosporins breakpoints that both organizations now 
adopted, it is unnecessary to edit susceptibility categories if an 
ESBL is found. A group of international experts in this field 
considered such advice is misguided [43]. It is prudent to continue 
to seek ESBLs directly and to avoid cephalosporins as treatment.    
7. In Hong Kong, if we apply the new ceftazidime breakpoint, three-
quarters of the ESBL-positive isolates would be re-classified from 
resistant to susceptible [44]. Caution with this approach is 
necessary whilst clinical data are limited [43]. 
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Table 1.6 Characteristics of ESBL and AmpC beta-lactamase 







Plasmid mediated Almost always 
(responsible for the 
spread) 
Most are chromosomal 
Plasmid increasingly 
reported 










Cefepime Variable Hydrolysed 
Carbapenem Not hydrolysed Not hydrolysed 
Examples TEM, SHV and CTX-M Enterobacter, Citrobacter 
and Serratia possess 
inducible beta-lactamase 
in their chromosomes 
 
 
1.5  Carbapenem-resistant Enterobacteriaceae 
 
Enterobacteriaceae can acquire resistance to carbapenem through 
production of carbapenemase, modification of outer membrane 
permeability and efflux pump (Table 1.7) [45].  
1. Carbapenemase, KPC-producing Klebsiella pneumoniae was first 
discovered from a clinical isolate through the ICARE surveillance in 
North Carolina in 1996 [46, 47] and followed by a substantial 
spread in New York [48], Israel [49] and Greece [50]. 
Enterobacteriaceae producing KPC has also been described in 
South America (Colombia, Brazil and Argentina) [51-53] and China 
[54, 55]. Other than K. pneumoniae, the KPC-enzyme has also been 
described in Enterobacter spp. and Salmonella spp. [47]. Infection 
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caused by carbanepem-resistant organisms increases the risk of 
complications and mortality [56]. 
2. New Delhi metallo-beta-lactamase 1 (NDM-1, Table 1.8) was first 
described in 2009 in a Swedish patient of Indian origin. He was 
hospitalized in India and acquired urinary tract infection caused by 
a carbapenem-resistant Klebsiella pneumonia [57]. Like other 
Metallo-beta-lactamase (MBL), the enzyme NDM-1 can hydrolyse all 
beta-lactam except aztreonam. Resistant to aztreonam is usually 
due to the coexisting ESBL or AmpC beta-lactamase. Majority of the 
NDM-1 producing organisms harbour other resistance mechanism, 
rendering it resistant to almost all classes of antibiotics with the 
possible exceptions of tigecycline and colistin [58, 59].  
3. NDM-1 producing Enterobacteriaceae has spread across Europe. In 
a recent survey conducted in 29 European countries, 77 cases were 
report in 13 countries [58]. Majority of the cases had a history of 
travel to India subcontinent. Many countries have developed their 
own national guidelines to deal with the problem of NDM-1 [58].  
4. The first case of NDM-1 producing E. coli has been described in 
Hong Kong in October 2009 from an Indian patient with urinary 
tract infection [60]. Several cases of IMP-4 were found in 
hospitalized patients since mid-2009 in Hong Kong (Figure 1.2) [61]. 
The first KPC-2 producing K. pneumoniae was described in 
February 2011 [62].  
5. The spread of NDM-1 is probably due to the huge selection 
pressure created by widespread non-prescription use of antibiotics 
in India [63] and involvement of promiscuous mobile elements in 
the gene’s dissemination [64]. 
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Table 1.7 Different classes of carbapenemase 
 Class A Metallo-beta-
lactamase 
Oxacillinase 
Molecular class Class A Class B Class D 
Functional class 2f 3 2d 
Chromosomal / 
plasmid 




















Mild inhibition by 
clavulanate 
Active site Serine Zinc ion Serine 
Carbapenem Hydrolysed Hydrolysed Hydrolysed 
Aztreonam Hydrolysed Not hydrolysed Not hydrolysed 






Hydrolysed Hydrolysed poorly 
#Seen in Hong Kong 
*Common in Hong Kong 
 
Table 1.8 Characteristics of NDM-1 producing organisms 
1. NDM-1 is a MBL (resistant to all beta-lactam except aztreonam) 
2. The blaNDM-1 gene is located in plasmid 
3. Resistant to aztreonam is due to coexisting ESBL and Amp C beta-lactamase 
4. Associated with other resistance mechanisms (resistant to multiple classes of 
antibiotics) 
5. Only susceptible to tigecycline and colistin 
6. The following Enterobacteriaceae can produce NDM-1: 
  a. Klebsiella pneumoniae (most common) 
  b. Escherichia coli 
  c. Other reported species: K. oxytoca, Citrobacter freundii, Enterobacter 
cloaceae, Morganella morganii, Proteus species and Providencia species 
7. Majority have a travel history and hospitalization in certain parts of the world 
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8. Transmission:  
  a. Indirect faecal-oral inter-human transmission 
  b. In both healthcare and community setting 
9. Control measure: 
  a. Hand hygiene and contact precautions 
  b. Laboratory support 
  c. Active surveillance [25]  
Reference: [15, 23] 
 
1.6 Carbapenem-resistant Acinetobacter baumannii 
 
Multidrug-resistant Acinetobacter baumannii (MRAB) is a widely used, 
and yet ill-defined and non-specific term (Figure 1.3). There is no 
internationally agreed definition for MRAB. Carbapenem is a critically 
important class of antimicrobial in the treatment of infection caused 
by Acinetobacter baumannii [65, 66]. Therefore, resistant to the 
carbapenems have been defined as a sentinel event [67-69]. Using the 
term carbapenem-resistant A. baumannii (CRAB) allows better 
communication and surveillance data could be comparable between 
different centers (Figure 1.3). Moreover, the recent rise in resistant 
strains of A. baumannii seen worldwide is mainly due to the 
dissemination of strains possessing the Class D OXA type beta-
lactamase [70-73]. Therefore, for surveillance purpose, the term CRAB 
reflects the current situation more accurately than MRAB.  
1. Resistant to carbapenem can be due to enzymatic degradation 
and efflux pump. However the recent spread in resistant strains 
of A. baumannii is mainly due to strains producing the Class D 
OXA type beta-lactamase [74, 75]. OXA-23, OXA-24 and OXA-58 
are the most common type of carbapenemase produced by A. 
baumannii. They contribute to carbapenem resistance in A. 
baumannii globally [75].   
2. The Metallo-beta-lactamases (MBLs) are Class B beta-lactamases 
which contain at least one Zinc ion at their active sites (Table 1.7). 
They are more potent carbapenemases and can hydrolyze all 
beta-lactamase except the monobactam, aztreonam [75]. However 
MBL is less commonly seen in A. baumannii. Due to the 
simultaneous presence of resistance determinant often carried on 
integrons, CRAB has concomitant resistant to other classes of 
antibiotics [16]. 
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3. In a recent local survey of CRAB, majority of the strains belonged 
to HKU1 and HKU2 clone [68]. OXA-23 was found in all HKU1 
isolates and correlated with high level of resistance to 
carbapenems. OXA-51 was found in both HKU1 and HKU2 clones. 
Chronic wound was found to be associated with MRAB 
colonization or infection, which acts as a potential reservoir for 
MRAB. This study demonstrated the spread of CRAB is due to the 
dissemination of two novel clones [70].  
4. Imipenem resistance was found to have a significant impact on 
the mortality on Acinetobacter bacteraemia [76], which is mainly 
accounted by the higher rate of discordant antimicrobial therapy. 
Acinetobacter resistant to imipenem was also found to have a 
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2.1 Antimicrobial stewardship programme 
 The present summary is based on an article in the Hong Kong Medical 
Journal [77]. 
2.1.1 What is antimicrobial stewardship programme? 
 The term antimicrobial stewardship (ASP) is defined as the optimal 
selection, dosage, and duration of antimicrobial treatment that results in 
the best clinical outcome for the treatment or prevention of infection, 
with minimal toxicity to the patient and minimal impact on subsequent 
resistance [78]. In practice, this involves prescribing antimicrobial 
therapy only when it is beneficial to the patient, targeting therapy to the 
desired pathogens and using the appropriate drug, dose, and duration. 
Thus, ASP should not be viewed simply as reduced use or a strategy for 
cost containment. Instead, by minimizing exposure to drugs, performing 
dose adjustments, reducing redundant therapy and targeting therapy to 
the likely pathogens, such activities can be viewed as a strategy to 
enhance patient safety. 
 ASP involves a multidisciplinary, programmatic, prospective, 
interventional approach to optimizing the use of antimicrobial agents. 
The multidisciplinary team typically includes clinical microbiologists, 
infectious disease physicians, infection control practitioners, and clinical 
pharmacists. Having members from other medical specialties, such as 
surgery and paediatrics, is also recommended. Multiple approaches have 
been employed to enforce hospital policies to limit or control 
antimicrobial use (Table 2.1- 2.3). Under the auspice of ASP, several 
behavioural methods have been used successfully to effect changes, 
including problem-based education, consensus guidelines, peer review, 
concurrent review, data feedback, computer-based reminders, financial 
incentives, and the use of opinion leaders [79, 80]. 
 Many professional societies and public health guardians including the 
World Health Organization, Infectious Diseases Society of America (IDSA), 
Alliance for the Prudent Use of Antibiotics (APUA), Food and Drug 
Administration (FDA), Centers for Disease Control and Prevention (CDC), 
National Institutes of Health (NIH) are supportive of programmes that 
promote optimal antimicrobial use [81, 82]. A few have even gone a step 
forward with action plans [81-84]. 
 In the real world, multiple factors are involved in the clinical decision 
making. Local and overseas experience indicate that availability of 
consultation service by clinical microbiologist / infectious disease 
physician is the most effective way for improving antimicrobial use [85, 
86]. 
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Table 2.1 Methods to implement antimicrobial control 
1. Administrative control 
a. Restriction of hospital formulary through the drug and 
therapeutics committee 
b. Cascade reporting of sensitivity results 
c. Use of antimicrobial order forms 
2. Guidelines, education & consultation 
a. Written hospital guidelines 
b. Educational efforts aimed at changing prescribing 
practices of clinicians 
c. Providing consultation from clinical microbiologist / 
infectious disease physician 
3. Surveillance 
a. Utilisation review with guidelines for rational and 
appropriate usage 
b. Ongoing monitoring and analysis of antimicrobial agents 
usage 
c. Ongoing surveillance of antimicrobial susceptibility 
4. Prospective audit with intervention 
a. Monitoring adherence to advice on choice of antimicrobial 
agents 
b. Usage feedback to clinicians 
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Table 2.2 Potential barriers to reaching the strategic goals 
Barrier Countermeasures and improvement 
strategies 
Ownership and accountability  
1. Lack of ownership and 
accountability for recognizing and 
reporting trends. 
2. Failure to integrate work of 
laboratory, infection control, 
medical, nursing, and intensive 
care-unit staff. 
1. Designate responsibility and 
accountability for the process. 
2. Set up a multi-disciplinary team to 
develop a collaborative system and 
monitor results. 
Staff knowledge and practice  
1. Lack of time for the laboratory 
and/or infection control staff to 
generate and analyze data. 
2. Lack of time for healthcare 
providers to examine and discuss 
data and inconsistent or 
erroneous interpretation of data 
by staff. 
1. Ensure adequacy of laboratory and  
infection-control staffing and prioritize 
activities of staff so that data can be 
generated and analyzed. 
2. Report data in an easy-to read/interpret 
format and, when appropriate, include 
data interpretation in the report. 
Physician attitudes  
1. Lack of trust in the hospital 
administration. 
1. Use a data-driven approach to cultivate 
trust; e.g. communicate regularly with 
physicians about trends in antimicrobial 
usage, cost, and resistance; feedback to 
individual physicians their performance 
results. 
Expertise  
1. Lack of expertise in biostatistics 
(e.g. presenting trends and 
analyzing data). 
1. Ensure availability of consultants, 
especially when designing analytic 








2.2 Switch therapy - conversion from I.V. to P.O. 
In the clinical situation of switch therapy use, oral antimicrobials 
replace intravenous usage for completion of therapy. Intravenous is 
almost always employed in serious infections to ensure maximal 
serum/tissue levels. With few exceptions such as meningitis, infective 
endocarditis, the majority of patients with infections do not require 
completion of the antimicrobial course with intravenous therapy. The 
following criteria have been developed for transition from intravenous 
to oral antimicrobial [88, 89]:  
1. Patient with no clinical indication for I.V. therapy. 
2. Patient is afebrile for >24 hours. 
3. The WBC count is normalizing (falling towards or <10x109/L). 
4. Signs & symptoms related to infection are improving. 
5. Patient is not neutropenic (neutrophil count >2 x109/L). 
6. Patient is able to take drugs by mouth (non-NPO).   
7. Patient with no continuous nasogastric suctioning. 
8. Patient with no severe nausea or vomiting, diarrhea, 
gastrointestinal obstruction, motility disorder. 
9. Patient with no malabsorption syndrome. 
10. Patient with no pancreatitis or active gastrointestinal bleeding or 
other conditions that contraindicated to the use of oral medications. 
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Table 2.3 Strategies for optimization of antimicrobial therapy 
Stages in the management of infection Strategies for optimization 
Empirical therapy (ET)  
x Document the presence of infection 
x Likely pathogens? 
x Likely susceptibility pattern 
x Community- or hospital-acquired 
infection? 
x Monotherapy or combination therapy? 
x Education [90] 
x Collection and analysis of local 
data 
x Pocket reference guide 
x Review of prescription of ‘big 
gun’ antibiotics by ASP team 
x ASP team to give immediate 
concurrent feedback (ICF) to 
prescribers 
 





Known-pathogen therapy (KPT)  
x Narrowest spectrum according to 
laboratory results 
x Follow guidelines on the judicious use of 
‘big gun’ antibiotics 
x Cascade reporting of sensitivity 
x Reporting of deviations from 
guidelines to clinical 
microbiologist / infectious 
disease physician 
x ASP team to give immediate 
concurrent feedback (ICF) to 
prescribers 
 
Switch therapy [91, 92]  
x A switch from intravenous to oral therapy 
x Criteria for switch therapy 
x Clinical diagnosis compatible with oral 
therapy 
x Patient has functioning gastrointestinal 
tract 
x Patient is afebrile (for >24 h) 
x Signs and symptoms related to infection 
are improving or resolved 
x The WBC count is normalizing 
 
x Review of patients on I.V. ‘big 
gun’ antibiotics by ASP team 
x Recommendation for ‘switching’ 
by ASP team 
  
Stop therapy  
x Type of infection 
x Clinical responses 








2.3 Tips on safe use of antibiotics in out-patient setting 
 
1. Understand the local prevalence of pathogens and associated antibiotic 
susceptibility profiles. Information on surveillance of antimicrobial 
resistance at community out-patient setting is available at CHP webpage 
[93]. 
2. A careful clinical evaluation (e.g. patient’s age, underlying comorbidity, 
duration and severity of symptoms, physical findings) is essential in 
making decision to use antibiotics. In some instances, clinical features 
alone may not reliably discriminate illness into bacterial and viral 
infections; point-of-care testing (e.g. flu A and B, CRP, WBC) can be 
helpful in this scenario. Upper respiratory tract infections are often viral 
in origin. In a study, antibiotics were prescribed in 68% of visits for 
symptoms of acute respiratory tract infections; among those, 80% were 
unnecessary according to CDC guidelines [94]. 
3. It is a good clinical practice to explain to the patient the reasons for 
giving or not giving antibiotics [95]. 
4. Whenever appropriate, prescribe the simplest regimen and shortest 
duration of treatment [96]. 
5. Take an ‘antibiotic timeout’ if possible, e.g. reassessing need of 
antibiotics after 48-72 hours. 
6. Advise patients to observe the following precautions while on antibiotics: 
z  Practice frequent hand hygiene; 
z  Eat or drink only thoroughly cooked or boiled items; 
z  Disinfect and cover all wounds; 
z  Wear mask if he/she has respiratory symptoms; 
z  Young children with symptoms of infection should minimize contact 
with other children. 
7. Take the opportunity to educate patients on proper use of antibiotics: 
z  Only take antibiotics prescribed for him/her; 
z  Do not share or use leftover antibiotics;  
z  Do not save antibiotics for the next illness;  
z  Do not ask for antibiotics when your doctor thinks you do not need 
them. In a study of paediatric care, doctors prescribe antibiotics 
62% of the time if they perceive pressure from parents and 7% of the 
time if they feel parents do not expect them [97]. 
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3.1.1 Situations in which the use of vancomycin is appropriate 
 
1. Treatment of serious infections caused by beta-lactam resistant 
Gram-positive bacteria (e.g. MRSA, coagulase-negative 
staphylococci) [98, 99]. 
2. Treatment of CA-MRSA in severe and extensive SSTI (multiple 
sites), rapid progression of cellulitis, immunosuppression, 
extreme of ages, area difficult to drain. 
3. Treatment of infections caused by Gram-positive bacteria in 
patients who have serious allergies to beta-lactam antimicrobial 
agents (e.g. anaphylactic reaction, Stevens-Johnson syndrome). 
4. When Clostridium difficile colitis fails to respond to metronidazole 
therapy or is severe and life-threatening. 
5. As prophylaxis for endocarditis following certain procedures 
inpatients at high risk for endocarditis; according to 
recommendation from the American Heart Association (e.g. as 
prophylaxis for genitourinary or gastrointestinal procedures in 
moderate or high-risk patients allergic to ampicillin/amoxicillin). 
6. As prophylaxis for major surgical procedures involving the 
implantation of prosthetic material or devices in known carriers 
of MRSA. For elective procedures, daily washing of skin and hair 
with a suitable antiseptic soap (e.g. 4% chlorhexidine liquid soap) 
and topical treatment of the anterior nares with nasal mupirocin 
ointment (for 3 to 5 days) are recommended before the 
procedures. Vancomycin may be less effective in preventing 
surgical wound infection due to methicillin-sensitive 
staphylococci [100].   
7. Addition of rifampicin as single agent or adjunctive not 
recommended. 
 
3.1.2 Situations in which the use of vancomycin is not advised 
1. Treatment of MRSA nasal carriage or colonization at other sites 
such as the isolation of MRSA from 
x Surface swab of superficial wounds 
x Surface swab of chronic ulcers 
x Surface swab of pressure ulcers 
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2. Routine surgical prophylaxis other than in a patient who has 
serious allergy to beta-lactam antimicrobial agents. 
3. Routine empirical antimicrobial therapy for neutropenic fever 
(except as recommended by the IDSA 2010 guidelines for the use 
of antimicrobial agents in unstable neutropenic patients with 
unexplained fever) [101]. 
4. Treatment in response to a single blood culture positive for 
coagulase-negative staphylococci, if other blood cultures taken 
during the same time frame are negative. 
5. Continued empirical use of presumed infections in patients 
whose cultures (blood, joint fluid, peritoneal fluid, pus, etc.), are 
negative for beta-lactam-resistant Gram-positive bacteria (e.g. 
MRSA). 
6. Systemic or local (e.g. antibiotic lock) prophylaxis against 
infection (or colonization) of indwelling (central or peripheral) 
intravascular catheters. 
7. As routine prophylaxis, before insertion of Hickman/Brovac 
catheter or Tenckhoff catheter. 
8. As part of the regimen for selective digestive tract 
decontamination. 
9. Primary treatment of Clostridium difficile colitis, except when it is 
severe and life-threatening. 
10. Routine prophylaxis for patients on continuous ambulatory 
peritoneal dialysis or haemodialysis. 
11. Treatment (e.g. chosen for dosing convenience) of infection 
caused by beta-lactam-sensitive Gram-positive bacteria in 
patients who have renal failure. 
12. Use of vancomycin solution for topical application (e.g. to burn 
wound, ulcers) or irrigation (e.g. of T-tube, drains). 
 
3.1.3 Vancomycin dosage in special situations and therapeutic 
drug monitoring 
1. In adults, the standard recommended dose of vancomycin is 30 
mg/kg/day (I.V. 1 g q12h or I.V. 0.5 g q6h in a normal 70 kg 
person). 
2. Therapeutic drug monitoring (TDM), Table 3.1 
Vancomycin exhibits time-dependent killing. Efficacy can usually 
be assumed if the trough concentration is sufficiently above the 
43
IMPACT Fourth Edition (version 4.0) 
 
 
MIC of the infecting organism (i.e. best if vancomycin levels at 
site of infection are maintained above MIC throughout the dose 
interval). MIC of most susceptible organisms (e.g. MRSA) ranges 
0.38-1.5 Pg/mL.  
Routine TDM is not indicated in most patients because 
vancomycin pharmacokinetics are sufficiently predictable that 
safe and effective vancomycin dosage regimens can be 
constructed on the basis of patient's age, weight and estimated 
renal function.   
 
Table 3.1 Indications for therapeutic drug monitoring 
(a) Renal impairment 
(b) ICU patients co-treated with dopamine and/or dobutamine 
[102] 
(c) Severe burn [103]  
(d) Morbid obesity [104]   
(e) Spinal cord injury [105] 
 
When TDM is indicated, check only trough level. There is no solid 
data to support the widely referenced trough range of 5-10 Pg/mL 
and accordingly, serum concentrations have been selected 
somewhat arbitrarily, based on pharmacology, retrospective 
studies, case reports and personal opinions. Due to the poor 
penetration of vancomycin to certain lung tissues, the 2005 
American Thoracic Society guideline recommend trough levels of 
15-20 Pg/mL for treatment of MRSA hospital-acquired 
pneumonia [106]. Current literature does not support peak 
concentration measurement [107].  
3. Dosage table/nomogram in patients with impaired renal function 
(Table 3.2) 
x An initial single dose of 15 mg/kg should be given to achieve 
prompt therapeutic serum concentration. Subsequent daily 
maintenance dose is to be determined according to dosage 
table/nomogram. 
x The dosage table/nomogram is not valid for functionally 
anephric patients on dialysis. For such patients, the dose 
required to maintain stable concentrations is 1.9 mg/kg/day 
(~130 mg/day for a 70 kg person). 
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x For patients with marked renal impairment, it may be more 
convenient to give maintenance doses of 0.25 g to 1 g every 3-7 
days. 
 
Table 3.2 Dosage table for vancomycin 
Creatinine clearance ( mL/min) Vancomycin dose (mg/24h) 
100 1 545 
90 1 390 
80 1,235 







Adapted from vancomycin package insert, July 2004. 
 
4. Vancomycin in morbidly obese patients [104, 107] (Table 3.3) 
x Serum clearance of vancomycin in morbidly obese patients 
was 2.3-2.5 times higher than that observed in non-obese 
subjects [104, 108].  
x Studies involving the pharmacokinetic of vancomycin in 
overweight and obese population have concluded that 
vancomycin clearance is best correlated with total body weight 
(TBW) [109]. In a study of 24 morbidly obese patients [104], 
the mean (±SD) vancomycin dose required to achieve steady 
state peak 25-35 Pg/mL and trough 5-10 Pg/mL were 1.9 g 
(±0.5 g) q8h. 
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body weight 200 kg, 
height 1.8 m, serum 
creatinine 80 Pmol/L 
Determine if the patient is 
morbidly obese 
TBW/IBW ratio: 
0.81.25 = normal 
>1.251.9 = obese 
>1.9 = morbid obesity 
200/70.7 = 2.8 
Determine dose of 
vancomycin 
30 mg/kg TBW/day 6 g per day if normal 
renal function. 
(administer as I.V. 2 g 
q8h; infuse each 2 g dose 




not accurate in morbidly 
obese patients. The 
Salazar-Corcoran 
equation appears to give 
the least biased estimate 
of CrCl 
 
Monitor trough level Target trough at 5-10 
Pg/mL 
Adjust dosing interval 
according to trough level 
Equations [110] : 
1. Ideal body weight (IBW) 
x IBW for male = 50 kg + 0.9 kg for each cm over 152 cm (2.3 kg for each 
inch over 5 feet) 
x IBW for female = 45.5 kg + 0.9 kg for each cm over 152 cm (2.3 kg for 
each inch over 5 feet) 
2. Salazar-Corcoran equation (for estimate of creatinine clearance in morbidly 
obese patients): 
Male patient, calculate CrCl as follows: 
(137age in years) u (TBW in kg u 0.285) + (12.1 u height in meter) 
0.58 u serum creatinine in Pmol/L 
  
Female patient, calculate CrCl as follows: 
 (146age in years) u (TBW in kg u 0.287) + (9.74 u height in meter)  
 0.68 u serum creatinine in Pmol/L 









a. Indicated for Gram-positive bacteria including MRSA with 
reduced vancomycin susceptibility MIC ≥2 μg/mL, 
vancomycin-resistant S. aureus (VRSA at MIC ≥4 μg/mL) and 
VRE and some mycobacteria (including Mycobacterium 
tuberculosis). 
b. Infections by MRSA in the case of vancomycin failure (e.g. 
unexplained breakthrough bacteraemia) and/or serious allergy. 
In these complicated circumstances, the opinion of a clinical 
microbiologist / infectious disease physician should be sought.  
2. Not active against Gram negative bacteria (e.g. Haemophilus 
influenzae, Moraxella catarrhalis). 
3. Most VRE identified in Hong Kong so far are susceptible to 
linezolid (both E. faecalis and E. faecium) at d4 Pg/mL and 
quinupristin/dalfopristin (E. faecium only, at d1 Pg/mL) [111]. 
However, multidrug resistant strains including linezolid-resistant 
clinical isolates of Enterococcus faecalis, Enterococcus faecium 
(VRE), Staphylococcus aureus, coagulase-negative staphylococci, 
Mycobacterium tuberculosis, which develop during therapy with 
linezolid have been reported. 
4. Dosage: P.O. or I.V. 600 mg q12h 
5. Side effects of linezolid includes myelosuppression; 
thrombocytopenia, anemia and neutropenia reported especially 
for treatment > 2 weeksġ [112]; lactic acidosis, peripheral 
neuropathy, optic neuropathy due to inhibition of 
intramitochondrial protein synthesisġ [113]; serotonin syndrome 
(fever, tremor, agitation and mental state changes), risk with 
concomitant SSRIġ[114].  
6. Please consult clinical microbiologist / infectious disease 
physician for the use of linezolid. 
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Active against Gram-positive bacteria only with proven in vitro 
activity against enterococci [including VRE and MRSA with 
vancomycin MIC ≥2 μg/mL]. 
Approved for use in serious skin and soft tissue infections (SSTI), 
MRSA bacteriaemia and right-sided endocarditis. 
2. Not indicated for pneumonia because of poor lung penetration 
and has not been studied for prosthetic valve endocarditis or 
meningitis. 
3. Dosage: I.V. 4-6ġmg/kg per day 
4. Side effects of daptomycin include myopathy and rhabdomyolysis 
especially in patients taking statins. Elevated creatinine kinase in 
2.8%. Cases of eosinophilic pneumonia related to the use of 
daptomycin has also been reportedġ[115]. 
5. Please consult clinical microbiologist / infectious disease 










1. Indications: MRSA, VRE and other multidrug-resistant organism 
with in vitro activity, when standard treatment has failed or are 
contraindicated (e.g. allergy).  
2. As for tetracyclines, this drug is not licensed for use in children. 
3. Poorly active or not active against the non-fermenters, such as 
Stenotrophomonas maltophilia, Pseudomonas species and CRAB. 
4. FDA Warnings: Reports showed an increased mortality in 
patients treated for nosocomial pneumonia, especially ventilator-
associated pneumonia, and also complicated skin and skin 
structure infections, complicated intra-abdominal infections and 
diabetic foot infectionsġ[116]. 
5. Dosage:  
x I.V. loading dose of 100ġmg, then 50ġmg every 12 hours.  
x Given as slow I.V. infusion (30-60 minutes).  
x Half maintenance dose (25ġ mg every 12 hours) for patients 
with severe liver disease (Child’s C). 
6. Side effects similar to tetracycline. 
7. Please consult clinical microbiologist / infectious disease 
physician for the use of tigecycline. 
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1. Main indication: treatment of multidrug-resistant Gram negative 
infections (e.g. CRE, pandrug-resistant A. baumannii, and P. 
aeruginosa). 
2. Poor lung penetration after intravenous administration. 
3. For pneumonia cases, use high intravenous dose with possible 
addition of nebulised colistin [117]. 
4. Dosage:  
a. Nebulised 1 million units (80ġmg) twice daily 




I.V. colomycin dosage and frequency 
 
!50  2 million units q8h 
20-50 1 million units q8h 
10-20 1 million units q12-18h 
<10 1 million units q24h 
 
5. Side effects: significant nephro- and neuro-toxicity 
6. Please consult clinical microbiologist / infectious disease physician 
for the use of colistin. 
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a. Indicated for treatment of complicated or uncomplicated 
cystitis caused by ESBL-positive Enterobactericeae. 
b. Systematic review showed 96.8% of ESBL-positive E. coli 
isolates and 81.3% of ESBL-positive Klebsiella pneumoniae 
isolates were susceptible to fosfomycinġ[118]. 
2. Inactive against enterococci. 
3. Dosage:  
a. Uncomplicated UTI: 3ġ g sachet P.O. x 1 dose with / without 
food 
b. Complicated UTI: 3ġg sachet P.O. every 2-3 days (up to 21 days) 
on an empty stomach 
4. Please consult clinical microbiologist / infectious disease 
physician for the use of fosfomycin in treatment of infections 
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3.7 Imipenem/meropenem/ertapenem 
3.7.1 Indications for using imipenem/meropenem/ertapenem 
1. Therapy of infections attributed to ESBL-positive bacteria (such 
as E. coli or Klebsiella spp.) such as: 
x Bacteraemia with isolation of ESBL-positive bacteria from 
blood culture. 
x Deep-seated infection with isolation of ESBL-positive bacteria 
from normally sterile body site or fluid (CSF, peritoneal fluid, 
pleural fluid, joint fluid, tissue, pus, etc.). 
x Nosocomial pneumonia, as defined by CDC guidelines, with 
isolation of ESBL-positive bacteria in a significant quantity, 
from a suitably obtained, good quality respiratory tract 
specimensa. 
2. Empirical therapy of neutropenic fever in high-risk patients. (As 
Ertapenem has no anti-pseudomonal activity, it should not be 
used as empirical therapy of neutropenic fever patients or 
patients with non-fermenters infection such as Pseudomonas 
aeruginosa and Acinetobacter.) 
 
Footnotes 
a Colonization of the respiratory tract by ESBL-positive bacteria, especially in 
mechanically ventilated patients is common. Antimicrobial therapy of colonization 
is not indicated. Isolation of ESBL-positive bacteria at the indicated quantity and 
specimen type is suggestive of infection rather than colonization (in descending 
order of clinical significance): 
1. 102-103 CFU/mL or moderate/heavy growth for protected specimen brush. 
2. 103-104 CFU/mL or moderate/heavy growth for bronchoalveolar lavage. 
3. Moderate/heavy growth for tracheal/endotracheal aspirate specimens with 
++ to +++ white cells and absent/scanty epithelial cells. 
4. Expectorated sputum (as defined by the American Society for Microbiology) 
with >25 WBC/low power field and <10 epithelial cells/low power field. 
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3.7.2 Situations/conditions in which 
imipenem/meropenem/ertapenem is not advised 
1. Treatment of colonization by ESBL-positive bacteria such as the 
isolation of these organisms from: 
x Surface swab of superficial wounds 
x Surface swab of chronic ulcers 
x Surface swab of pressure ulcers 
2. Empirical therapy of most community-acquired infections 
including pneumonia, appendicitis, cholecystitis, cholangitis, 
primary peritonitis, peritonitis secondary to perforation of 
stomach, duodenum or colon, skin/soft tissue infections, etc. 
3. As known-pathogen therapy for infections caused by organisms 
susceptible to other beta-lactams. 
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3.8 Once daily aminoglycosides 
1. Once daily aminoglycoside (ODA) dosing is as effective as 
multiple-daily dosing in most clinical settings. The former dosing 
probably results in a lower risk of nephrotoxicity than the latter. 
With ODA, any differences in the relative nephrotoxicity of the 
aminoglycosides are likely to be small. Nonetheless, there is 
considerable confusion on the dose and how to monitor serum 
aminoglycoside levels when using ODA dosing [119]. 
2. Dosing to be based on actual body weight unless the patient is 
morbidly obese (i.e. 20% over ideal body weight, IBW).  
 
Aminoglycoside dosing weight for morbidly obsess 
patient 
= ideal body weight + 0.4 (actual body weight - IBW). 
Formula for calculation of ideal body weight is as follows: 
Ideal body weight for male = 50 kg + 0.9 kg for each cm 
over 152 cm (2.3 kg for each inch over 5 feet) 
Ideal body weight for female = 45.5 kg + 0.9 kg for each cm 
over 152 cm (2.3 kg for each inch over 5 feet) 
 
3. For patient with impaired renal function, give the first dose 
according to body weight as above. Subsequent frequency of 
administration (of the same dose) to be based on the estimated 
creatinine clearance of the patient according to the following table. 
 
Cockcroft-Gault formula  
To estimate creatinine clearance, calculate as follows  
Creatinine clearance for male patient (mL/min) = (140-age) 
x 1.2 x ideal body weight (kg) /serum creatinine (mmol/L)  
(Female: 0.85 u above value) 















<20 Follow serial levels to determine time of  
next dose (level <1 Pg/mL) 
 
aAt present, the dosage of aminoglycoside to use in a ODA strategy has 
not been clearly determined. Dosages for gentamicin, tobramycin and 
netilmicin have ranged from 3 to 7 mg/kg, and amikacin dosages have 
ranged from 11 to 30 mg/kg. On the basis of local experiences and a 
recent consensus meeting, the following doses are recommended for 
initial therapy in local Chinese: for gentamicin and tobramycin, 3.5 
mg/kg; netilmicin, 4.4 mg/kg and amikacin, 15 mg/kgġ[119].  
 
4. Therapeutic drug monitoring (TDM) [120-122]  
 Routine TDM not indicated in patients under the following 
conditions: 
(a) Receiving 24-h dosing regimen,  
(b) Without concurrently administered nephrotoxic drugs (e.g. 
vancomycin, amphotericin B, cyclosporin),  
(c) Without exposure to contrast media,  
(d) Not quadriplegic or amputee,  
(e) Not in the ICU,  
(f) Younger than age 60 years, 
(g) Duration of planned therapy less than 5 to 7 days.  
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If therapeutic drug monitoring is indicated (e.g. due to impaired 
renal function), check level and interpret the result as follows: 
a) For once daily (extended-interval) dosing, obtain a single blood 
sample after the first dose between 6-14 h after the start of the 
infusion. Do not check pre- and post-dose.  
b) Write down the time in number of hours after last dose in request 
form (e.g. 8 h post-dose). This is essential for result interpretation. 
c) When result becomes available, plot the value on the Hartford 
normogram (Table 3.4) and work out the appropriate dosing 
interval by the following table. With this method, the size of each 
dose need not be reduced.  
 
Post-dose level Dosing interval 
Level falls in the area 
designated q24h  
Dose at an interval of every 24 h 
Level falls in the area 
designated q36h  
Dose at an interval of every 36 h 
Level falls in the area 
designated q48h  
Dose at an interval of every 48 h 
Level on the line Choose the longer interval 
Level off the normogram at 
the given time 
Stop the scheduled therapy, 
obtain serial levels to determine 
the appropriate time of the next 
dose 
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Table 3.4 Hartford Hospital once-daily aminoglycoside normogram 
for gentamicin and tobramycin 
The Hartford normogram has not been validated in the following 
category of patients: paediatrics, pregnancy, burns (>20%), ascites, 








3.9 Antifungal agents 
 
1. Recently, an increasing number of antifungal agents have become 
available. The mechanism of action for the major antifungal 
classes is summarized in Table 3.5. 
2. It is important to note that there are significant within and 
between class variations in the antifungal spectrum of the agents 
(Table 3.6). They also differ in their pharmacokinetic properties 
(Table 3.7 and 3.8). The need to adjust dosage in renal and 
hepatic dysfunction is summarized in Table 3.9. 
3. Echinocandins are not active or show very limited activity against 
Cryptococcus neoformans, Trichosporon beigelii, dematiaceous 
moulds, Zygomycetes, Fusarium species and dimorphic fungi 
(Blastomyces, Histoplasma, Coccidiodes) because these fungi do 
not have the target for the echinocandins to act. 
4. Fluconazole show potent activity against Candida albicans. It is 
also active against non-albicans Candida but MICs are higher, 
especially for C. glabrata.  
5. Analysis of fungaemia data in local hospitals showed that about 
10% of the isolates were potentially resistant to fluconazole and 
the echinocandins (Figure 3.1).  
6. Table 3.10 summarized the antifungal agents that have been 
evaluated in randomized clinical trials (RCT) for the five major 
indications. In general, the different agents were non-inferior to 
each other for the major outcomes. In several studies, superior 
results were demonstrated for certain outcomes. Table 3.11 
showed a suggested scheme for choosing antifungals. 
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Table 3.5 Mechanisms of antifungal action 





















Amphotericin B Bind to and make 
fungal cell 
membrane ‘leaky’ 
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Table 3.9 Need for dosage adjustment in renal and hepatic dysfunction 
  Anidulafungin 
 






    
Mild 
 
50-80 No No No No 
Moderate 
 
31-49 No No No Avoid I.V. 
Severe 
 







    
Mild 
 





7-9 No No Reduce from 







>9 No ? ? ? 
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*Agent with superior results for some outcomes is underlined. 
Invasive aspergillosis: posaconazole superior and safer than liposomal 
amphotericin B with fewer nephrotoxicity and hepatotoxicity [136]. Voriconazole 
superior and safer than amphotericin B [127]. 
Neutropenic fever: caspofungin superior and safer than liposomal amphotericin B 
with fewer nephrotoxicity [141] and comparable [142]. 
Antifungal prophylaxis: micafungin superior to fluconazole in HSCT patients [139] 
and comparable [140]. Itraconazole superior to fluconazole in acute myelogenous 
leukaemia (AML) and myelodysplastic syndrome (MDS) patients [145] and HSCT 
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Part IV: Recommendation for the empirical therapy of 
common infections 
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4.2 Guidelines on the use and choice of antibiotics in 
severe acute pancreatitis 
1. Criteria for severity assessment of acute pancreatitis (Table 4.2). 
Most acute pancreatitis is mild. Severe acute pancreatitis (SAP) 
occurs in about 5-13% of all patients with mortality rates of 30% 
[213, 214]. SAP is commonly defined as having any of the following 
4 criteria: (a) organ failure; (b) local complication such as necrosis, 
pseudocyst, or abscess; (c) Ranson score t3; or (d) at least 8 of the 
APACHE II criteria [215]. Of all markers available, CRP is the single 
most useful parameter in predicting the severity of acute 
pancreatitis [216].   
2. Infection risk and antibiotic prophylaxis: Pancreatic or 
peripancreatic infection occurs in 30-40% patients who have >30% 
pancreatic necrosis in CT staging. In patients with necrosis 
involving more than one-half of the pancreas, the incidence of 
subsequent infection is as high as 40–70%. Infection typically 
occurs in the second or third week after presentation [217]. 
Infection usually occurs at least 10 days after the onset of SAP. In 
patients with severe acute pancreatitis, the early data suggests that 
prophylactic antibiotic reduce infection and mortality [218-222], but 
the most recent double blind randomized studies, published in 2004, 
2007 and 2009 cannot confirm a beneficial effect in reduction of 
mortality [213, 223, 224]. Inconsistent conclusion was also noted in 
two recently published meta-analysis [225, 226]. Further 
investigation has to be performed in this area. 
3. Choice of antibiotics (Figure 4.1): However, if antibiotic is to be 
given, the agents should be able to penetrate into pancreatic tissue. 
Good pancreatic tissue concentrations have been documented for 
cefotaxime, piperacillin, imipenem and metronidazole [227]. In 
terms of activity, it seems reasonable to provide coverage for the 
enteric Gram-negative bacilli and anaerobes. Carbapenem group of 
antibiotic should be reserved for the most severe form of disease (i.e. 
SAP with highly suspected or documented pancreatic necrosis).  
4. Duration of prophylactic antibiotics: 5 to 14 days depending on 
disease severity and patient progress [218-222, 227-229]. Excessive 
and prolonged antibiotic use in this setting is known to cause fungal 
super-infection and emergence of antibiotic-resistant bacteria, and 
should be avoided [230, 231].   
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5. Consider CT or US guided-FNA of necrotic area for culture if 
secondary pancreatic infection is suspected and if fever or 





Table 4.2 Criteria for severity assessment of acute pancreatitis 
Box 1. Ranson’s criteria Box 2. Organ failure 
One point for each of: 
At admission 
x Age > 55 years 
x WBC >16 000/PL 
x Glucose >11.1 mmol/L (>200 
mg/dL) 
x LDH >350 IU/L 
x AST >250 IU/L 
During initial 48 hours 
x Haematocrit decrease >10% 
x BUN increase >1.8 mmol/L 
(>5 mg/dL) 
x Calcium <2 mmol/L (<8 
mg/dL) 
x PaO2 <60 mm Hg 
x Base deficit >4 mEq/L 
x Fluid sequestration >6 L 
 
 CVS: shock (SBP <90 mm 
Hg or mean arterial pressure 
<70 mm Hg or inotropic 
support) 
 Resp: PaO2 <60 mm Hg or 
ventilator dependent 
 Renal: Urea >7.4 mmol/L or 
Creatinine >250 Pmol/L or 
requiring renal replacement 
 Gastrointestinal: bleeding 
>500 mL in 24 hours 
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Mild Severe (Box 1 & 2) 
Moderately severe 
Only Ranson t3  
but no organ failure and  
CRP <150 mg/L 
Very severe 
Organ failure;  
CRP t150 mg/L;  
CT proven pancreatic necrosis 
Options 
1. Cefuroxime + 
metronidazole 












4.3 Management of community-acquired pneumonia 
 
4.3.1 General considerations and principles 
1. A number of guidelines on the management of community-
acquired pneumonia (CAP) were released or updated recently. 
While these guidelines were drawn on the basis of the same set of 
literature, patient stratification and specific suggestions still vary 
quite a bit [206-208]. 
2. All agreed that S. pneumoniae is the most common pathogen in 
CAP including those without an identifiable etiology. Hence, the 
choice of agents for empirical therapy should consider the 
regional data on prevalence and risk factors for drug-resistant S. 
pneumoniae (DRSP). 
3. Appropriate antimicrobial therapy should be initiated within 8 
hours of hospitalization. Prior studies indicated that compliance 
with this recommendation is associated with a significant 
reduction in mortality [232]. 
4. Factors to be considered in choosing empirical therapy for 
CAP: 
(a) Place of therapy (outpatient, inpatient ward, or intensive 
care unit). 
(b) Role of atypical pathogens (e.g. Chlamydia pneumoniae, 
Mycoplasma pneumoniae and Legionella spp.) is increasingly 
being recognized. ATS guidelines even suggested that all 
patients should be treated for the possibility of atypical 
pathogen infections [206]. 
(c) Presence of modifying factors including risk factors for 
DRSP (e.g. age >65 years., beta-lactam therapy within past 
3 months, alcoholism, multiple medical comorbidities, 
exposure to a child in a day care centre), enteric Gram- 
negatives (residence in a nursing home, underlying 
cardiopulmonary disease, multiple medical comorbidities, 
recent antibiotic therapy), and P. aeruginosa (e.g. 
bronchiectasis). 
(d) Emerging resistance patterns among the major pathogens. 
In Asia, including Hong Kong, high prevalence of macrolide 
resistance has been reported among mycoplasma 
pneumoniae strains in recent years [233-236]. 
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(e) Emerging pathogens including those of regional 
significance such as CA-MRSA (association with necrotizing 
pneumonia and influenza virus coinfection), Klebsiella 
pneumoniae (association with disseminated infection, liver 
abscess and diabetes mellitus) and Burkholderia 
pseudomellei (occur in melioidosis endemic area during 
rainy season) [237, 238]. 
5. Several antibiotics active against P. aeruginosa, including 
cefepime, imipenem, meropenem and piperacillin-tazobactam are 
generally active against DRSP. They can be used for patients 
having specific risk factors for P. aeruginosa. 
6. If a macrolide is relied upon for coverage of H. influenzae, the 
newer macrolides (e.g. clarithromycin or azithromycin) should be 
used instead of erythromycin. 
7. For most patients, appropriately chosen initial antibiotic therapy 
should not be changed in the first 72 hours, unless there is 
marked clinical deterioration. 
8. Most patients with CAP will have an adequate clinical response 
within 72 hours. After the patient has met appropriate criteria, 
switch from I.V. to oral therapy can be made. 
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4.3.2 Management of community-acquired pneumonia in the era 
of pneumococcal resistance: conclusions from the CDC 
working group 
1. Comparative studies of adults and children have reported that 
pneumonia due to penicillin-nonsusceptible pneumococci (most 
had MIC >0.1-1 Pg/mL) does not influence the outcome of 
pneumonia treatment [239, 240]. At higher level of resistance 
(penicillin MIC 2-4 Pg/mL), recent evidence suggests that risk of 
mortality or suppurative complications were increased [241, 242]. 
In one study [243], the observed increase in mortality was 
confined to patients with pneumococcal isolates with penicillin 
MIC of t4 Pg/mL. 
2. It is important to note that different breakpoints are used for 
interpretation of penicillin susceptibility (Table 4.3) [244, 245].  
Table 4.3 Interpretation of penicillin susceptibility for S. pneumoniae        
(CLSI. Jan 2012) 
Period , Syndrome, Route of administration Penicillin or Amoxicillin MIC (Pg/mL)  
Susceptible Intermediate Resistant 
Meningitis, I.V. Penicillin d 0.06 - t 0.12 
Non-Meningitis, I.V. Penicillin d 2 4 t 8 
Non-Meningitis, Oral (high dose) 








By modifying the breakpoints, it is hope that there will be 
decreased use of broad-spectrum antimicrobial therapy in favour 
of more narrow-spectrum therapy. Patients with pneumococcal 
pneumonia caused by strains with penicillin MIC d1 Pg/mL can 
be treated appropriately with optimal dosage of I.V. penicillin and 
several other P.O./I.V. beta-lactams. Comparative anti-
pneumococcal activities of commonly used beta-lactams are 
shown in Table 4.4. 
3. Vancomycin is not routinely indicated for treatment of CAP or for 
pneumonia caused by DRSP. 
4. The CDC working group does not advocate the use of newer 
fluoroquinolones for first line treatment of CAP. The reasons are: 
(a) Most penicillin-nonsusceptible S. pneumoniae pneumonia 
can be appropriately treated with a beta-lactam with good 
anti-pneumococcal activity at optimal dosage. 
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(b) Concerns that resistance among pneumococci will rapidly 
emerge after widespread use of this class of antibiotics. 
(c) Their activity against pneumococci with high level penicillin 
resistance (MIC t4 Pg/mL) makes it important that they be 
reserved for selected patients with CAP. 
5. Indications for use of fluoroquinolones in CAP:   
(a) Adults for whom one of the first line regimen has already failed. 
(b) Allergic to alternative agents. 
(c) Documented infection due to pneumococci with high level 
penicillin resistance (penicillin MIC t4 Pg/mL). 
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4.3.3 Regional considerations for S. pneumoniae 
References: [1, 2, 177, 178, 204, 246-249]  
1. In Hong Kong, reduced susceptibility to penicillin (Figure 4.2) and 
resistance to macrolides were high in both hospital [178, 204] 
and community settings [246, 247].  
2. Erythromycin resistant isolates are also resistant to the newer 
macrolides/azalides such as clarithromycin and azithromycin 
[250]. In 2005-2011, the age group-specific rates of macrolide 
resistance among 844 invasive pneumococcal isolates were as 
follows: 79.8% in <5 years, 75.9% in 5-17 years, 61.6% in 18-64 
years and 58.9% in ı65 years. Accordingly, macrolides should 
not be used as sole therapy for empirical treatment of presumed 
pneumococcal infection.   
3. Globally, resistance to fluoroquinolones among the pneumococci 
is low (<1-2%). Hong Kong is one of the rare exceptions in which 
fluoroquinolone resistance (levofloxacin MIC t8 Pg/mL) is  
emerging among the S. pneumoniae, especially among respiratory 
isolates from elderly patients with chronic lung diseases [178].  
4. In view of the above, adherence to the CDC guidelines on the use 
of the fluoroquinolones seems appropriate. Moreover, 
tuberculosis is prevalent in Hong Kong and was reported to 
account for ~10% of CAP in the elderly. Excess use of 
fluoroquinolones in CAP may lead to: (1) delay in diagnosis of 
tuberculosis; (2) increased fluoroquinolone resistance among 
Mycobacterium tuberculosis [251, 252]. Hence, this class of agents 
is not recommended as first line (or routine) therapy in Hong 
Kong for CAP. In this regard, extra-care need to be exercised in 
using fluoroquinolones in patients with risk factors for 
fluoroquinolone-resistant S. pneumonia [211]:  
x Presence of COPD; 
x Nosocomial pneumococcal infection; 
x Residence in old age home; 
x Past exposure to fluoroquinolones; and 
x Nosocomial pneumococcal infection. 
5. Ciprofloxacin and ofloxacin should not be used to treat 
pneumococcal infection. Use of a suboptimal dose of 
fluoroquinolone should be avoided (e.g. the dose/frequency 
approved by FDA for levofloxacin in CAP is 500 mg/day). Use of 
<500 mg and in divided doses should be avoided as these have 
been showed to be associated with the emergence of 
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fluoroquinolone-resistant S. pneumonia [205]. If a respiratory 
fluoroquinolone is indicated, there is evidence to suggest that the 
more potent ones (e.g. gemifloxacin, moxifloxacin, gatifloxacin) 
are less likely to lead to development of resistance. 
6. Penicillin G (I.V.) or ampicillin (P.O./I.V.) or amoxicillin (P.O./I.V.) 
are generally viewed as the beta-lactam drugs of choice for 
treating infections with penicillin-susceptible and penicillin-
intermediate strains of S. pneumoniae. The following beta-lactams 
are not recommended because of poor intrinsic activities against 
S. pneumoniae: penicillin V, all first generation cephalosporins, 
cefaclor, cefixime, ceftibuten, and loracarbef. 
7. Lung infections involving strains with intermediate susceptibility 
to penicillin (MIC 0.1-1 Pg/mL) may be treated with I.V. penicillin 
G or oral amoxicillin (high dose). 
8. Penicillins combined with beta-lactamase inhibitors (ampicillin-
sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam) are 
active against beta-lactamase-producing organisms including H. 
influenzae, M. catarrhalis, and methicillin-sensitive S. aureus. 
Except in patients with mixed infection, these drugs offer no 
advantage over penicillin G or amoxicillin for the treatment of S. 
pneumoniae pneumonia, including those due to penicillin-
resistant strains because beta-lactamase is not produced by S. 
pneumoniae. The MIC of ampicillin, amoxicillin, piperacillin for 
most local strains were similar to that of penicillin. However, the 
MIC of ticarcillin is increased disproportionately among penicillin 
non-susceptible strains. 
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Figure 4.2 Susceptibility of 844 invasive pneumococcal isolates to 
penicillin and cefotaxime according to patient age 
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Table 4.4. Comparative activities of commonly used beta-lactams 
against S. pneumoniae with different levels of 
penicillin susceptibility 
Agent Penicillin MIC 
 d0.06 Pg/mL 0.121 Pg/mL 2 Pg/mL t4 Pg/mL 
Penicillin V +++ +   
Penicillin G  +++ +++ ++ r 
Ampicillin P.O. +++ ++ r  
Ampicillin I.V. +++ +++ ++ r 
Amoxicillin P.O. +++ ++ +  
Piperacillin +++ ++ +  
Ticarcillin ++ +   
Cefotaxime +++ +++ ++ r 
Ceftriaxone +++ +++ ++ r 
Cefepime +++ ++ + r 
Cefuroxime I.V. +++ ++ +  
Cefuroxime P.O. +++ ++ r  
Cefpodoxime +++ ++   
Ceftazidime +++ +   
Cefaclor +++    
Cefixime/ceftibuten +++    
Imipenem/meropenem +++ +++ +  
Penicillin MIC interpretation criteria (mg/L) for intravenous penicillin 
G: meningitis ≤0.06 sensitive, ≥0.12 resistant; nonmeningitis ≤2 
sensitive, 4 intermediate and ≥8 resistant. 
Approximate in vitro activity was indicated by: - inactive, + weak 
activity, ++ good activity, +++ excellent activity.  
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Part VI: Guidelines for surgical prophylaxis 
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General principles in surgical prophylaxis 
1. Duration of prophylaxis: The duration of antimicrobial 
prophylaxis should not routinely exceed 24 hours (1 dose at 
induction and 2 more doses postoperatively, i.e. 3 doses in total). 
There is wide consensus that only a single dose of intravenous 
antimicrobial agent is needed for surgical prophylaxis in the great 
majority of cases. Published evidence shows that antimicrobial 
prophylaxis after wound closure is unnecessary and could lead to 
emergence of resistant bacteria. Most studies comparing single- 
with multiple-dose prophylaxis have not shown benefit of additional 
doses.  
2. Timing: For many prophylactic antimicrobial agents, the 
administration of an initial dose should be given within 30 minutes 
before incision (coinciding with the induction of anesthesia) to 
achieve an adequate tissue concentration at the time of initial 
incision. This can be facilitated by having the anesthesiologist 
administer the drug in the operating room at induction.  
3. Antimicrobial dosing: The dose should be adequate based on the 
patient’s body weight. An additional dose of antimicrobial agent 
should be given (intra-operatively) if the operation is still continuing 
after two half-lives of the initial dose or massive intra-operative 
















Cefazolin 1-2 g 2-5  
Cefuroxime 1.5 g 3-4 
Clindamycin 600-900 mg 3-6 
Amoxicillin-
clavulanate 1.2 g 2-3 
Ampicillin-
sulbactam 1.5 g 2-3 
Metronidazole 500 mg 6-8 
Vancomycin 1 g infuse over 60 min 6-12 
*In patient with normal renal function and not morbidly obese. 
 
 
Table 6.2 Antimicrobial prophylaxis in clean operations 
Type of 
operation Indications Recommended drugs
c 
Cardiaca y Prosthetic valve 




y Open heart 
surgery 
y I.V. cefazolin 1 gb 
then every 4 hours.  
 
Note: The duration of 
antimicrobial 
prophylaxis should not 
be longer than 48 
hours. 
Thoracica y Pulmonary 
resection 
y Closed tube 
thoracostomy for 
chest trauma 
y I.V. cefazolin 1 gb    
OR 
y I.V. cefuroxime 1.5 g  
OR 
y I.V. amoxicillin-
clavulanate 1.2 ge 
 
Vascular y Abdominal aortic 
operations 
y Prosthesis 
y Groin incision 
y Lower extremity 
amputation for 
ischaemia 
Table 6.1 Suggested initial dose and time to re-dose for 
selected antimicrobial agents used for surgical 
prophylaxis 
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operation Indications Recommended drugs
c 
Neurosurgerya y Craniotomy 
y V-P shunt 
y I.V. cefazolin 1 gb       
OR 
y I.V. cefuroxime 1.5 g 
y Re-exploration or 
microsurgery 
y I.V. cefuroxime 1.5 g  
OR  
y I.V. amoxicillin-
clavulanate 1.2 ge 
Orthopaedic & 
Traumatologya 
y Total joint 
replacement with 
prosthesis 
y Internal fixation 
of closed 
fractures 
y I.V. cefazolin 1 gb     
OR 
y I.V. cefuroxime 1.5 g  
 
Note: Antimicrobial 
agents should be 
completely infused 
before inflating the 
tourniquet. 





















gentamicin) or (I.V. 
ceftriaxone 2 g or 
other third 
generation 
cephalosporin  Ʋ  






is 3 days for Gustilo-
Anderson grade I and 
II open fractures and 




 y Antimicrobial 
prophylaxis is not 
indicated 
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Nasal   





clavulanate 1.2 ge  
OR 
If pseudomonas is 
suspected: 
y I.V. amoxicillin-
clavulanate 1.2 ge  
+ I.V. gentamicin   
OR   
y I.V. amoxicillin-
clavulanate 1.2 ge  
+ I.V. ceftazidime 
1-2 g  
Ear y Myringotomy 
y Tympanostomy Tube 
Insertion 









y Gastric ulcer 
y Malignancy 
y H2 blocker 
y Proton pump inhibitor 
y Morbid obesity 
y Gastric bypass 
y Percutaneous 
endoscopic gastrostomy 











y Oesophageal operation 
with manipulation of 
pharynx 
y I.V. cefuroxime 
1.5 g    OR 
y I.V. cefazolin 1 gb 
Ʋ metronidazole 
500 mg 
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y Age more than 70 years 
y Acute cholecystitis / 
pancreatitis 
y Obstructive jaundice  
y Common bile duct 
stones 
y Morbid obesity 
y Intra-operative 
cholangiogram 
y Bile spillage 
y Pregnancy 
y Immuno-suppression 
y Insertion of prosthetic 
devices 
y Laparoscopic converts 
to laparotomy       
y I.V. amoxicillin-
clavulanate 1.2 ge  
OR  
y I.V. cefuroxime 









y Biliary obstruction y P.O. ciprofloxacin 
500-750 mg 2 
hours prior to 
procedure   
OR  
y I.V. tazocin 4.5 g 
1 hour prior to 
procedure 
Appendectomy  y I.V. amoxicillin-
clavulanate 1.2 ge  
OR  
y I.V. cefuroxime 
1.5 g + I.V. 
metronidazole 
500 mg  
Colorectal y Most procedures require 




clavulanate 1.2 ge  
OR 
y I.V. cefuroxime 
1.5 g + I.V. 
metronidazole 
500 mg  
Oral 
y P.O. neomycin 
and erythromycin 
base 1 g each 
t.i.d. the day 
before operation 
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y I.V.  cefazolin 1 gb   
OR  
When vaginal 
wound is present: 
y I.V. cefuroxime 
1.5 g + I.V. 
metronidazole 
500 mg      
 OR  
y I.V. amoxicillin-
clavulanate 1.2 ge 
 
Note: For Cesarean 
Section, the initial 
dose of 
antimicrobial agents 






y Emergency procedures 




Abortionf  Antimicrobial 
prophylaxis should 
be based on 
individual clinical 
condition. 
Urology y Significant bacteriuria 
y TURP, TURBT, TUR  
y Stone operations,  
y Nephrectomy 
y Total cystectomy 
y Treat according 
to mid-stream 
urine culture 
result prior to 
elective 
procedures 
Hernia Repaird y Non Mesh Hernia 
Repair  
Antimicrobial 
prophylaxis is not 
indicated 
y Adult Hernia Mesh 
Repair 
y I.V. cefazolin 1 gb  
OR  
y I.V. cefuroxime 
1.5 g  
Mastectomy  y Without implant y Antimicrobial 
prophylaxis is not 
indicated 
y With implant / foreign 
body 
y I.V. cefazolin 1 gb  
OR  
y I.V. cefuroxime 
1.5 g  
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Indications  Recommended drugsg 
Ruptured 
viscus  
For treatment of 
established infection  
 
y I.V. cefuroxime 1.5 g + 
I.V. metronidazole 500 
mg   OR  
y I.V. amoxicillin-
clavulanate 1.2 ge    
 
(Therapy is often 
continued for about 5 
days) 




y I.V. cefazolin 1-2 gb  OR 
y I.V. cefuroxime 1.5 g  
OR  
y I.V. amoxicillin-
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Remarks for Tables 6.2-6.4: 
aFor hospitals or units with a high incidence of postoperative wound 
infections by MRSA or MRSE, screening for MRSA may be indicated to 
identify patients for additional preoperative measures such as 
Chlorhexidine bath, 2% Mupirocin nasal ointment  [Bactroban Nasal] 
and/or the use of vancomycin as preoperative prophylaxis [257, 258]. 
 
bGive cefazolin 2 g for patients with body weight greater than 80 kg.  
For patients allergic to cefazolin, vancomycin 1 g infused over 1 hour 
should be given after premedication with an antihistamine. Rapid I.V. 
administration may cause hypotension, which could be especially 
dangerous during induction of anesthesia. 
 
cThe dose of antimicrobial agents recommended in the guidelines is 
based on adult patient with normal renal function. Special attention 
should be paid to patient with renal impairment, on renal replacement 
therapy, or if there is potential drug-drug interaction. Consultation to 
Clinical Microbiologist, Infectious Disease Physician and Clinical 
Pharmacist is required in complicated cases. 
 
dAmoxicillin-clavulanate may be used if the operation is such that 
anaerobic coverage is needed, such as in diabetic foot, hernia repair 
with bowel strangulation or incarcerated / strangulated hernia or 
mastectomy with implant or foreign body. 
 
eAmoxicillin-clavulanate and ampicillin-sulbactam are similar in 
spectrum coverage and centers may choose to use ampicillin-
sulbactam. 
 
fThe optimal antibiotic and dosing regimens for abortion are unclear. 
The antimicrobial prophylaxis for abortion stated in ROCG clinical 
guidelines is Level C recommendations and may be suitable. They 
include: Metronidazole 1 g rectally at the time of abortion plus 
Doxycycline 100 mg orally twice daily for 7 days, commencing on the 
day of abortion; OR Metronidazole 1 g rectally at the time of abortion 
plus Azithromycin 1 g orally on the day of abortion.  
 
gAntimicrobial agents should be considered postoperatively for 
operations with suppurative, ruptured and gangrenous conditions. 
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Part VII: Cost and recommended dosage of commonly-
used antimicrobial agents
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Trade name / 
generic  
Dosage form 
(unit cost, HK$) 
Usual adult regimen 
(daily dose, route, 
dosing interval) a 
Amikacin [119] Amikin  0.25 g vial ($41.2) 
0.5 g vial ($60) 
I.V. 15 mg/kg q24h 
(750 mg q24h)b or 7.5 
mg/kg q12h 
Amoxicillin Generic  250 mg cap. ($0.1) 
125 mg/5 mL syr. 
($0.15/mL) 










0.6 g vial ($14.1) 
1.2 g vial ($7.8) 
375 mg tab. ($0.72) 
1 g  tab. ($ 1) 
156 mg/5 mL syr. 
($0.13/mL) 
457 mg/5ml ‘b.i.d. syr.’ 
($0.34/mL) 
I.V. 1.2 g q8h  
 
P.O. 375-750 mg t.i.d. 
P.O. 1 g b.i.d. 
P.O. 312 mg (10 mL) 
t.i.d. (syr.) 
P.O. 914 mg (10 mL) 
b.i.d. (syr.) 
Ampicillin Generic 500 mg vial ($1.7)  
250 mg cap. ($0.24) 
500 mg cap. ($0.4) 
125 mg/5 mL syr. 
($0.44/mL) 
I.V. 1 g q6h  




Unasyn 750 mg vial ($11.8)  
375 mg tab. ($5.93) 
250 mg/5mL syr. 
($1.53/mL) 
I.V. 1.53 g q6h  
P.O. 375 mg t.i.d. 
Azithromycin Zithromax 500 mg vial ($165) 
250 mg tab. ($2.92) 
200 mg/5ml syr. 
($1.67/mL) 
I.V. 500 mg q24h 
P.O. 500 mg on first 
day then 250 mg once 
daily 
Cefazolin Generic 1 g vial ($3) I.V. 1 g q8h 
Cefepime Maxipime 1 g vial ($102) 
2 g vial ($204) 
I.V. 12 g q12h 
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Trade name / 
generic  
Dosage form 
(unit cost, HK$) 
Usual adult regimen 
(daily dose, route, 
dosing interval) a 
Cefoperazone+ 
sulbactam 
Sulperazon 1 g vial ($33) I.V. 1-2 g q12h 
Ceftazidime Fortum 1 g vial ($25.7) 
2 g vial ($51.7) 
I.V. 1 g q8h 
Cefotaxime Generic 1 g vial ($11.5) I.V. 1 g q68h (max 12 
g/day)  
Ceftriaxone Rocephin / 
Genericş 
0.25 g I.M. ($80) 
1 g vial ( $14.50)^ 
I.M. 250 mg once 
I.M./I.V. 12 g/day 
q1224h (max 4 g/day) 
Cefuroxime Generic 0.75 g vial ($4.69) I.V. 0.751.5 g q8h 
Cefuroxime-
axetil 
Zinnat 125 mg tab. ($3.8) 
250 mg tab. ($1) 
125 mg/5 mL 
suspension 
($1.11/mL) 
P.O. 250500 mg b.i.d. 
Cephalexin Generic 250 cap. ($0.32) 
500 cap. ($0.71) 
P.O. 250500 mg q.i.d. 
Ciprofloxacin Generic^ / 
Ciproxin 
200 mg vial ($69.45)^ 
400 mg vial ($635) 
250 mg tab. ($0.78))^ 
I.V. 200400 mg q12h  
 
P.O. 500750 mg b.i.d. 





500 mg vial ($78) 
250 mg tab. ($1.16)^ 
500 mg tab. ($2.32)^ 
125 mg/5 mL syr. 
($0.42/mL) 
I.V. 500 mg q12h  
P.O. 250500 mg b.i.d. 
Clindamycin Generic^ / 
Dalacin C 
150 mg/mL in 2 ml 
vials  ($10)^ 
150 mg cap. ($2.6) 
I.V. 600 mg q8h (max 
2.7 g/day)  
P.O. 150300 mg q.i.d. 
Cloxacillin Generic 500 mg vial ($4.4) 
250 mg cap. ($0.3) 
500 mg cap. ($0.38) 
I.V. 0.51 g q6h (max 
12 g/day)  
P.O. 500 mg q.i.d. 
Colistin Colomycin 1.MU vial ($85)  I.V. 1-2 MU q8h  
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Trade name / 
generic  
Dosage form 
(unit cost, HK$) 
Usual adult regimen 
(daily dose, route, 
dosing interval) a 
Daptomycin Cubucin 500 mg vial ($1250) 4 mg/kg (cSSSI) or     
6 mg/kg (S. aureus 
bloodstream infection) 
q24h 
I.V. 250-500 mg q24h 
Doxycycline Generic 100 mg tab. ($0.9) 
I.V. form is no longer 
available in HK 
P.O. 100 mg b.i.d. 
Ertapenem Invanz 1 g ($228) I.V. 1 g q24h 
Erythromycin Generic 500 mg vial ($110)  
250 mg tab, ($0.54) 
200 mg/5 mL syr. 
($4.95/mL) 
I.V. 500 mg q6h  
P.O. 250500 mg 
q.i.d. 
Flucloxacillin Generic 125 mg/5 ml solution 
($0.14/mL) 




4 g vial ($500) 
3 g sachet (Not in HA 
formulary) 
I.V.  8-12 g/day (100-
200 mg/kg/day)   





Generic 80 mg/2 mL ($2.43) I.V. 3.6 mg/kg/day 
q24h (180 mg q24h) b 
or 1.2 mg/kg/dose 
q8h  
Imipenem Tienam 500 mg vial ($62) I.V. 500 mg q6h 
Levofloxacin 
 
Generic  500 mg vial ($125) 
100 mg tab. ($0.88) 
250 mg ($1.65) 
I.V. 500 mg q24h  
P.O. 500 mg once 
daily 
Linezolid Zyvox 600 mg vial ($430) 
600 mg tab. ($410) 
20 mg/mL syr. 
($13.63/ml) 
I.V./P.O. 600 mg q12h 
Meropenem Meronem 500 mg vial ($82) 
1g vial ($128) 
I.V. 1 g q8h 
Metronidazole Generic 500 vial ($4.10) 
200 mg tab. ($0.13) 
I.V. 500 mg q8h 
P.O. 400 mg t.i.d. 
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Trade name / 
generic  
Dosage form 
(unit cost, HK$) 
Usual adult regimen 
(daily dose, route, 
dosing interval) a 
Minocycline Generic 100 mg vial ($116) 
100 mg cap. ($3.5) 
50 mg cap. ($1.9) 
P.O. 100 mg b.i.d. 
Moxifloxacin Avelox 400 mg vial ($270) 
400 mg tab. ($23) 
I.V. 400 mg q24h 
P.O. 400 mg q.i.d. 
Netilmicin 
[119] 
Netromycin 50 mg vial ($19.8) 
150 mg vial ($37.5) 
I.V. 4.4 mg/kg q24h 
(200 mg q24h) b or I.V. 
2.2 mg/kg q12h  
Penicillin G Generic 1 MU vial ($5.90) I.V. 12 million unit 
q46h (max 24 million 
unit/day) 
Piperacillin Generic 4 g vial ($26.9) I.V. 4 g q6h 
Piperacillin-
tazobactam 
Tazocin 4.5 g vial ($74.2) I.V. 4.5 g q68h 
Teicoplanin Targocid 200 mg vial ($400) I.V. 400 mg x 1 dose 
then 200 mg q24h 
Ticarcillin-
clavulanate 
Timentin 3.2 g vial ($54.5) I.V. 3.2 g q46h 
Tigecycline  Tygacil 50 mg vial ($333) I.V. 100 mg loading 
then 50 mg q12h 
Tobramycin 
[119] 
Generic 40 mg/mL 2 ml vial 
($48) 
I.V. 3.6 mg/kg q24h 
(180 mg q24h) b or 1.2 
mg/kg q8h 
Vancomycin Generic 500 mg vial ($13.5) I.V. 1 g q12h or I.V. 
500 mg q6h (i.e. 30 
mg/kg/day)  
P.O. 125 mg q.i.d. 
(for refractory C. 
difficile colitis) 
a Typical dosages in a 70 kg person with normal renal function. Dosage 
modification may be necessary for (i) the elderly; (ii) the very obese individuals (in 
whom the distribution volume of water-soluble drugs may be smaller than 
expected from body mass); (iii) those with renal failure and/or (iv) liver failure. 
b Dosage for a typical 50 kg person given. Once daily administration of 
aminoglycoside is appropriate for most infections with the possible exceptions of 
neutropenic fever, infective endocarditis and in the presence of severe renal failure. 
 
118
IMPACT Fourth Edition (version 4.0) 
 
 
Table 7.2 Cost comparison of selected I.V. antibiotics 
Antibiotics  Usual dosage Cost (HK$/day) 
Aminoglycosides   
I.V. Gentamicin* (3.5 mg/kg/day) 180 mg q24h 7 
I.V. Netilmicin* (4.4 mg/kg/day) 200 mg q24h 75 
I.V. Tobramycin* (3.5 mg/kg/day) 180 mg q24h 144 
I.V. Amikacin* (15 mg/kg/day) 750 mg q24h 101 
Penicillins   
I.V. Ampicillin  0.5-1 g q6h 7-14 
I.V. Cloxacillin 0.5-1 g q6h 18-35 
I.V. Amoxillin-clavulanate  1.2 g q8h 23 
I.V. Ampicillin-sulbactam  1.5 g q8h 71 
I.V. Ticarcillin-clavulanate  3.2 g q6h 218 
I.V. Piperacillin 4 g q8h 81 
I.V. Piperacillin-tazobactam  4.5 g q8h  




Cephalosporins   
I.V. Cefuroxime  750 mg q8h 14 
I.V. Cefazolin 1 g q8h 9 
I.V. Ceftriaxone 1 g q12h 29 
I.V. Cefotaxime  1 g q8h 35 
I.V. Cefoperazone-sulbactam 
(Sulperazon) 
1 g q12h 
(1 g q8h) 
66 
(99) 
I.V. Cefepime 1 g q12h 204 
I.V. Ceftazidime  1 g q8h 77 
 
Carbapenems   
I.V. Meropenem  0.5 g q8h 
(1 g q8h) 
246 
(384) 
I.V. Imipenem-cilastatin  500 mg q6h 248 
I.V. Ertapenem  1 g q24h 228 
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Antibiotics  Usual dosage Cost (HK$/day) 
Fluoroquinolones   
I.V. Moxifloxacin  
P.O. Moxifloxacin 
400 mg q24h 
400 mg once daily 
270 
23 
I.V. Levofloxacin  
P.O. Levofloxacin 
500 mg q24h 
500 mg once daily 
125 
3 
I.V. Ciprofloxacin  
P.O. Ciprofloxacin 
400 mg q12h 




Macrolides   
I.V. Clarithromycin  500 mg q12h 156 
I.V. Azithromycin 500 mg once daily 165 
 
Others   
I.V. Metronidazole  500 mg q8h 12 
I.V. Vancomycin 1 g q12h 54 
I.V. Linezolid  
(P.O. Linezolid) 
600 mg q12h 




Note: Approximate cost updated as of October 2011 in HA. 
 *Dosage for a typical 50 kg person
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Table 7.3 Cost comparison of systemic antifungal agents 
Antifungal agent Usual dosage Cost 
(HK$/day) 
P.O. Itraconazole  
(capsule)  
P.O. Itraconazole 
(solution)   
I.V.  Itraconazole  
200 mg b.i.d. 
 
200 mg b.i.d. 
 






P.O. Fluconazole  
P.O. Fluconazole 
(suspension) 
I.V.  Fluconazole  
100-400 mg daily 
100-400 mg daily 
 







Prophylaxis:   
200 mg q8h 
558 
P.O. Voriconazole  
I.V.  Voriconazole 
200 mg b.i.d. 
200 mg q12h  
757 
1620 
I.V. Anidulafungin Candidemia: 
Loading 200 mg (Day 1) 
Maintenance 100 mg q24h 
 
Esophageal candidiasis: 
Loading 100 mg (Day 1) 






I.V. Micafungin Prophylaxis in HSCT: 
50 mg q24h 
 
Candidemia, acute disseminated 
candidiasis, candida peritonitis 
and abscesses:  100 mg q24h 
 
Esophageal candidiasis:  










I.V. Caspofungin Invasive aspergillosis: 
Loading 70 mg (Day 1) 
Maintenance 50 mg q24h 
1521-1980 
I.V. Amphotercin B  
(1 mg/kg/day) *           
50 mg q24h 195 
I.V. Liposomal 
amphotericin B  
(3 mg/kg/day) * 
150 mg q24h 4995 
 
 
Note: Approximate cost updated as of October 2011 in HA. 
 *Dosage for a typical 50 kg person 
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Table 7.4 Dosage of antimicrobial agents for CNS infections 
Antibiotics*  Recommended doses Cost (HK$/day) 
I.V. Cefotaxime  2 g q4h 138 
I.V. Ceftriaxone  2 g q12h 58 
I.V. Cefepime  2 g q8h 612 
I.V. Meropenem  2 g q8h 768 
I.V. Ampicillin  2g q4h 41 
I.V. Penicillin G  34 MU q4h 106-142 
I.V. Metronidazole  500 mg q6h 16 
I.V. Vancomycin  1 g q12h 54 
P.O. Rifampin**  600 mg once daily 1 
 
Note: *  Dosage for a typical body weight t70 kg and normal renal 
function. 
** Rifampicin should only be used in combination with another 
antibiotic for meningitis by certain bacteria (e.g. multi-
resistant Streptococcus pneumoniae or MRSA) with 
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Table 7.5 Intra-peritoneal antibiotic dosing recommendations 
for patients with CAPD peritonitis 
Antibiotics Intermittent dosing (once daily) * 
(Add drug into 1 bag/day unless 
otherwise specified) [341] 
Aminoglycosides  
Amikacin 2 mg/kg 
Gentamicin 0.6 mg/kg 
Netilmicin 0.6 mg/kg 
Tobramycin 0.6 mg/kg 
Cephalosporins   
Cefazolin 15 mg/kg 
Cefepime 1 g 
Ceftazidime 1-1.5 g 
Others  
Ampicillin-sulbactam  2 g q12h 
Imipenem 1 g q12h 
 
* In patients with residual renal function, the drug dose should be 
empirically increased by 25%. 
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Part VIII: Other issues 
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1. Studies have shown that 70-90% of patients who gave a history of penicillin 
allergy could actually tolerate penicillin. 
2. It has been estimated that less than 15% of patients with penicillin allergy 
are still allergic ten years after their last reaction. 
3. There is extensive cross-reactivity between drugs in the penicillin family.  
Patients who are allergic to one penicillin drug must therefore avoid other 
members of the family. 
4. On the other hand, unnecessary avoidance of penicillin in patients who are 
not actually allergic would result in extra cost and overuse of drugs that 
should be reserved for treating drug-resistant organisms, such as 
vancomycin. 
5. Certain penicillin drugs are commonly associated with drug rashes.  These 
reactions, although usually mild, can nevertheless result in patient 
dissatisfaction.  
6. Skin testing with major and minor determinants of penicillin can very 
reliably rule out IgE-mediated penicillin allergy.  These tests however might 
not be available in all hospitals. 
7. Patients with IgE-mediated beta-lactam allergy can be successful 
desensitized just prior to starting treatment. 
 
8.1.2. Dealing with patients with a remote history of penicillin allergy 
 
1. Determine the date of the last reaction, the type of reaction, the timing of 
the reaction and other extenuating circumstances, such as infectious 
mononucleosis and other infections (Figure 8.1). 
2. Patients who give a history consistent with severe drug allergy, including 
Stevens-Johnson syndrome, toxic epidermal necrolysis and drug 
hypersensitivity syndrome must not be given drugs from the same family 
again. 
3. Patients who give a history consistent with an IgE-mediated reaction 
(urticaria, angioedema, anaphylaxis) should use an alternative agent (see 
8.1.5 below).  If penicillin is strongly indicated, skin testing can be 
performed to assess the risk of anaphylaxis (Figure 8.2).  If skin testing is 
not available, rapid oral desensitization can be performed (Table 8.1) with 
informed consent just prior to drug administration. 
4. In patients who give a history of minor drug rash, penicillin is not absolutely 
contraindicated.  However, the physician should first consider using an 
alternative agent to avoid patient dissatisfaction.  Under circumstances 
where the use of penicillin is clinically desirable, the treating physician 
should carefully explain the rationale and obtain the patient's informed 
consent.  This should be recorded in the patient's medical record.  It is also 
prudent to give a test dose of 1/10th of the treatment dose first and observed 
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8.1.3. Dealing with patients with a definite history of IgE-mediated penicillin 
allergy 
 
1. Patient who had reactions that were medically verified as IgE-mediated 
should use an alternative agent. 
2. If penicillin is strongly indicated, desensitization should be carried out with 
informed consent just prior to drug administration. 
  
8.1.4. Dealing with patients with a history of cephalosporin allergy 
 
1. Cephalosporins generally have a much lower risk of allergic reactions 
compared to penicillin because their beta-lactam ring is rapidly broken 
down in vivo. 
2. To deal with patients with a remote history of cephalosporin allergy, see 
section A. 
3. Cross-reactivity tends to occur between cephalosporins with similar side 
chains.  It is therefore possible to substitute a cephalosporin with side-
chains different from that of the offending drug (Table 8.2). 
4. Since cephalosporin allergy is due to side-chain reactivity, skin testing with 
the native drug can reliably predict the likelihood of IgE-mediated reactions. 
5. Therefore, if the patient is allergic to a clearly identified cephalosporin and 
no satisfactory alternative is available, the physician can choose another 
cephalosporin with different side-chains.  Skin testing should be performed 
with this drug to rule out the risk of IgE-mediated reaction.  The drug can 
then be administered after obtaining the patient's informed consent. 
 
8.1.5. Choosing an alternative drug for patients with beta-lactam allergy 
 
1. As cephalosporins have a spectrum of antimicrobial activity similar to 
penicillin, they are actually good alternatives for patients with penicillin 
allergy. 
2. Unfortunately, product inserts often list penicillin allergy as a 
contraindication to the use of cephalosporins.  This information was based 
on early experiences with first generation cephalosporins and is no longer 
up to date.  However, there are medico-legal implications when using 
cephalosporins in patients with penicillin allergy. 
3. Second, third and fourth generation cephalosporins have negligible cross-
reactivity with penicillin and are good alternatives, as long as one chooses 
agents that do not share similar side-chains with penicillin G, ampicillin or 
amoxicillin (Table 8.2). 
4. Patients with penicillin allergy have a higher risk of becoming allergic to any 
drug in general.  This fact should be communicated to the patient and the 
rationale for using the alternative agent explained.  Informed consent should 
be obtained and recorded in the medical record. 
5. Carbapenems can also be safely used in patients with penicillin and 
cephalosporin allergy if clinically indicated. 
6. Macrolides, quinolones, lincomycins and aminoglycosides do not cross-react 
with beta-lactams. 
7. Vancomycin should only be considered as a substitute if clinical 
circumstances dictate its use, i.e. MRSA, enterococcus, etc. 
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Table 8.1 Oral beta-lactam desensitization protocol* 
 
Dose  Concentration (mg/ml) Volume (ml) Time  Reaction 
1 0.1 0.3 0:00  
2 0.1 0.6 0:15  
3 0.1 1.2 0:30  
4 0.1 2.5 0:45  
5 0.1 5 1:00  
     
6 1 1 1:15  
7 1 2 1:30  
8 1 4 1:45  
     
9 10 0.8 2:00  
10 10 1.6 2:15  
11 10 3.2 2:30  
12 10 6.4 2:45  
     
13 100 1.2 3:00  
14 100 2.5 3:15  
 
1. Prepare stock solution of beta-lactam drug that you wish to use at 100 mg/ml.   
2. Make serial dilutions at 10 mg/ml, 1 mg/ml, 0.1 mg/ml. 
3. Administer doses at 15-minute intervals. 
4. Have epinephrine 1:1000 on stand-by at bedside. 
5. Once successfully desensitized, begin treatment immediately. 
6. To maintain desensitized state, patient must not interrupt treatment for more 
than 2 days.  Otherwise, patient would need to be desensitized again. 
 
* Reference: [342] 
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Table 8.3 Risk of cross-reactivity between different beta-lactams 
Allergic to Drug of concern Risk of cross-reactivity 
Cephalosporin Penicillin 8.3% - 25.5% in two series [344, 345]   
*Cephalosporin with structures similar or 
identical to penicillin have 3-fold increase in risk 
 Carbapenem Imipenem 2% and meropenem 1% in one series 
   
Penicillin  Cephalosporins 10.9% with most involving cephalothin and 
cefamandazole [346] 
 Carbapenems Meropenem 0.9%, imipenem 0.9% [347-349] 
 All first 
generation 
cephalosporins 
Odds ratio: first generation cephalosporins 4.2, 
Second generation cephalosporins 1.1 and third 
generation cephalosporins 0.8 [350] 
 Cephalexin 31% in one series with 16 patients [351] 
   
Amoxicillin Cefadroxil  38% (cefadroxil has identical side chain to 
amoxicillin) [352] 
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Figure 8.2 Beta-lactam skin testing 
 
Stock test solutions: 
1. Benzylpenicilloyl poly-L-lisine* 0.04 mg/ml 
2. Minor determinant mix** 0.5 mg/ml  
3. Am oxicillin 20 mg/ml*** 
4. Ampicillin 20 mg/ml 
5. Cephalosporins 20 mg/ml 
 
Note that all stock concentrations are in miligram per mililiter. 
 
Precautions 
This should only be conducted by persons with the proper training. 






* DAP penicillin kit (Diater Laboratories) 
** MDM vial (sodium benzylpenicillin, benzylpenicilloic acid, sodium 
benzylpenicilloate), DAP penicillin kit (Diater Laboratories) 
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8.2 Tips on laboratory diagnostic tests 
 
8.2.1 Urinary Legionella antigen test (UAT) 
x The majority of Legionnaire’s disease (LD) is caused by 
Legionella pneumophila serogroup 1 [353]. The test kit most 
commonly used in HA hospitals detects L. pneumophila 
serogroup 1 ONLY (Table 8.4). 
x Most of the HA hospitals offering this test can guarantee a 
turnaround time of 1 day [354].  
x Although more than 80% of patients with LD excrete antigens 
in urine during day 1 to 3 of symptoms [353], the UAT can 
remain negative in the first 5 days of the illness. Therefore a 
negative UAT during the early phase of illness does not exclude 
LD, and UAT should be repeated [355].  
x The UAT of majority of LD patients will turn negative within 60 
days [353]. However, the longest documented duration of 
antigen excretion was 326 days [356]. Therefore a positive UAT 
can indicate either current or past infection. 
x Pneumonia caused by Streptococcus pneumoniae and urinary 
tract infection caused by E. coli and Staphylococcus aureus can 
result in false positive UAT (very weak band after 15 minutes). 
The specificity is around 97.1%. If very weak bands in the first 
15 minutes are discounted and re-examined after 45 minutes 
to look for increased band intensity, the specificity can 
increase to 100% as false positive bands would not intensify 
[357]. Other causes of false positivity include rheumatoid-like 
factors, freeze-thrawing of urine, and excessive urinary 
sediments [356].  
x The sensitivity of UAT is variable, ranging from 70% to 80% 
[356].  A Spanish group evaluated the sensitivity of the test 
during a large Legionella outbreak in Spain. They found that 
severe LD had a higher sensitivity (>80%) [358]. Therefore, a 
negative UAT in a patient with mild atypical pneumonia does 
not exclude the diagnosis of LD. Other laboratory 
investigations for diagnosing LD should be performed (Paired 
serology, culture with BCYE ± supplements and PCR of lower 
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Table 8.4 Key points in the use of UAT 
1. Can detect L. pneumophila serogroup 1 ONLY. 
2. Short TAT (within 1 day). 
3. UAT can be negative within the first 5 days. 
4. A positive UAT result usually turns negative within 
60 days. 
5. Sensitivity: 70–80% 
Specificity: approaches 100% 
6. Negative UAT does not exclude LD 
7. False positive UAT: 
- Pneumonia caused by S. pneumoniae 
- Urinary tract infection caused by E.coli, S. aureus 
- Rheumatoid-like factors 
- Freeze-thrawing of urine 
- Excessive urinary sediments 
 
8.2.2 Diagnosis of catheter-associated bloodstream infection 
x The presence of bacteria in the blood stream is detected by the 
continuous-monitoring blood culture system in HA hospitals. 
The automatic device continuously measures the metabolic 
product produced by microorganisms. When a certain cutoff 
value is reached, the monitoring machine would indicate 
positivity of the blood culture bottle of interest, where the bottle 
would then be removed and subcultured. The time to positivity 
(TTP) would be affected by the initial bacterial inoculum, i.e. the 
higher the inoculum, the shorter the TTP [359, 360].  
x In-vitro studies have noted a linear relationship between the 
bacterial inoculum size and TTP of blood culture [361]. The TTP 
in patients with bacteraemia is variable, ranging from <7 hours 
to >20 hours, depending on the infecting organism and severity 
of the disease (Table 8.5). 
x The differential time to positivity (DTP) is a reliable and simple 
technique to diagnose catheter-associated blood stream infection 
(CABSI) without the need for removal of the catheter [362].  A 
high central to peripheral blood culture colony ratio is indicative 
of CABSI. When blood is drawn simultaneously from central 
venous catheter and peripheral, catheter blood culture positive 
2 hours earlier than peripheral blood culture is highly 
indicative of CABSI [361, 363]. (Information of TTP can usually 
be obtained from the microbiology laboratory) (Table 8.6). 
x In a meta-analysis, the sensitivity and specificity of DTP in 
diagnosing CABSI is 89% and 87% respectively [362].  
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Table 8.5 TTP of blood culture of different organisms 




19.9 r 19.4 h 
15h (14.1 r 9.8) h 




CFU <10 : >20 h 
CFU >100 : d16 h 
[362] 
S. pneumoniae 14 h [366, 367] 
E. coli 
ESBL-pos E. coli 








10.4 r 7.9 h 
14.5 r 9.5 h 
8.6 r 3.2 h 
[370] 
Candida 24.9 – 25.9 h [371] 
 
Table 8.6 Diagnosing CABSI by DTP 
1. Blood culture performed with aerobic and anaerobic 
blood culture bottle from central venous catheter 
and peripheral site respectively.  
2. Approximately equal volume of peripheral blood 
and catheter blood (from ALL lumens) should be 
drawn simultaneously under aseptic technique.  
3. Label clearly “Suspected catheter associated blood 
stream infection” to alert laboratory staff so that all 
bottles are incubated into the continuous 
monitoring blood culture system at the same time. 
4. The time for blood culture broth to turn positive is 
recorded. (The TTP can be obtained from 
microbiology laboratory.) 
5. If catheter blood TTP is >2 hours early than 
peripheral blood TTP, then the patient is likely to 
have CABSI. 
6. The DTP is valid only if: 
- The volume of peripheral blood injected into the 
blood culture bottles is approximately equal to 
the catheter blood 
- Blood culture are taken simultaneously 
- Blood culture are incubated into the blood 
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8.2.3 Prosthetic joint infection 
x Multiple intra-operative specimens (5 to 6 specimens) should be 
obtained during revision surgery of an infected prosthetic hip 
joint, since isolation of an indistinguishable organism from 3 or 
more independent specimen is highly predictive of infection. Use 
of separate instruments to obtain the specimen could reduce the 
chance of false positivity and cross-contamination [372]. 
x Slow-growing, fastidious organisms and biofilm-forming sessile 
phase bacteria may be difficult to detect in routine bacterial 
culture. Seven days of culture can detect up to 70% of the 
infections, while prolonged bacterial culture for 2 weeks can 
detect the remainder [373].  
x BACTEC blood culture bottles could be used for the diagnosis of 
prosthetic joint infection. Intraoperative specimens (synovial 
fluid or homogenized infected tissue) could be injected into 
BACTEC blood culture bottles and incubated in an automated 
monitoring machine [374-376]. BACTEC was found to have high 
sensitivity and specificity in diagnosing prosthetic joint infections, 
compared to conventional laboratory culture methods [376]. 
BACTEC was also found to have the shortest TTP comparing 
with different laboratory enrichment methods [376].  
 
8.2.4 Culture of sterile body fluid 
x Use of BACTEC blood culture bottles can increase the sensitivity 
for recovery of microorganisms from sterile body fluids [377-380]. 
It can also reduce the time to detection and increase the yield of 
isolation of fastidious organisms [378-380].  
x CAPD peritonitis may be difficult to diagnose, especially when 
caused by fastidious organisms, when the dialysate contains 
very low number of organisms or when prior antibiotics have 
been given. Using BACTEC and BacT/ALERT bottles to culture 
the dialysate fluid can increase the sensitivity for recovering 
microorganisms, especially fastidious bacteria [379, 381]. Direct 
inoculation of ascitic fluid into blood culture bottles at the 
bedside was found to have a significantly higher sensitivity and 
shorter time for detection of bacterial growth [382].  
x The use of BACTEC and BacT/ALERT blood culture bottles 
could increase the yield of microorganisms from pleural fluid 








3GC  Third generation cephalosporins 
AACP American Association of Colleges of Pharmacy 
ACP-ASIM American College of Physicians- 
American Society of Internal Medicine 
AECB Acute exacerbation of chronic bronchitis 
APUA Alliance for the Prudent Use of Antibiotics 
ASP Antimicrobial stewardship programme 
b.i.d. Twice a day 
BLBLI Beta-lactam/beta-lactamase inhibitor  
CA-MRSA Community-associated methicillin-resistant 
Staphylococcus aureus 
CAP Community-acquired pneumonia 
cap. Capsule 
CDC Centers for Disease Control and Prevention 
CLIS Clinical and Laboratory Standards Institute 
COPD Chronic obstructive pulmonary disease 
CRHD Chronic rheumatic heart disease 
CRKP Ceftazidime-resistant Klebsiella pneumoniae 
CT Computerised tomography 
D5 5% dextrose solution 
DDD Defined daily dose 
DRSP Drug-resistant Streptococcus pneumoniae 
ESBL Extended-spectrum beta-lactamase 
ET Empirical therapy  
FDA Food and Drug Administration 
FNA Fine needle aspiration 
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HA-MRSA Healthcare-associated methicillin-resistant 
Staphylococcus aureus 
HACEK Haemophilus parainfluenzae, H. aphropilus, 
Actinobacillus, Cardiobacterium, Eikenella, 
Kingella 
IBW Ideal body weight 
IDSA Infectious Diseases Society of America 
IE Infective endocarditis 
I.M. Intramuscular  
I.V. Intravenous 
IVDA Intravenous drug abuser 
KPT Known-pathogen therapy 
MIC Minimal inhibitory concentration 
MRPA Multidrug-resistant Pseudomonas aeruginosa  
MRSA Methicillin-resistant Staphylococcus aureus  
MSSA Methicillin-sensitive Staphylococcus aureus 
NCCLS National Committee for Laboratory Standards 
NIH National Institutes of Health 
ODA Once daily aminoglycosides 
P.O. Per oral 
PPU Perforated peptic ulcer 
PVL Panton-Valentine leukocidin 
q.i.d. Four times daily 
syr. Syrup 
tab. Tablet 
TBW Total body weight 
TDM Therapeutic drug monitoring   
t.i.d. Three times daily 
US Ultrasound 
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VRE Vancomycin-resistant enterococcus 
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A 
Abortion, surgical prophylaxis, see “pregnancy”   
Abscess 22 
- brain 72t 
- breast 76t 
- liver 74t 
Acinetobacter 20t, 52, 82t, 99, 101t 
- Acinetobacter baumannii 18t, 50, 97t, 134t 
- Acinetobacter baumannii, carbapenem-resistant (CRAB) 19t, 29, 30, 33f 
- Acinetobacter baumannii, multidrug-resistant (MRAB) 29, 30, 33f 
Acute bacterial exacerbation of COPD 78 
Acute exacerbation of chronic bronchitis (AECB) 78t 
Acute pyelonephritis 77t 
Aeromonas 71t, 74t 
Allergy 47, 49, 71t, 78t, 79t, 82t, 102t, 125, 126, 130f 
Amikacin 20t, 33f, 55, 97t, 98t, 115t, 119t, 123t 
Aminoglycosides 19t, 25, 33f, 80t, 97t, 98t, 99t, 100t, 101t, 119t, 123t, 126 
- once daily 54, 55, 57t 
Amoxicillin 42, 70t, 78t, 79t, 90t, 93, 95t, 99t, 104t, 115t, 126, 129t, 131 
Amoxicillin-clavulanate 20, 70t, 71t, 73t, 74t, 76t, 77t, 78t, 79t, 80t, 82t, 90t, 93, 99t, 
100t, 102t, 104t, 107t, 109t, 110t, 111t, 112t, 113, 115t, 119t 
AmpC beta-lactamase 19t, 26t, 27, 28t, 98t, 101t 
Amphotericin B 59t, 60t, 64t, 65t, 121t 
- liposomal 64t, 121t 
Ampicillin 19t, 20t, 24, 42, 69t, 70t, 71t, 72t, 75t, 78t, 93, 95t, 115t, 119t, 122t, 126, 131 
Ampicillin-sulbactam 20t, 69t, 70t, 73t, 76t, 77t, 93, 95t, 97t, 99t, 102t, 107t, 113, 115t, 
119t, 123t 
Amputation, surgical prophylaxis 107 
Anidulafungin 59t, 60t, 62t, 63t, 64t, 65t, 121t 
Antifungals 58, 59t, 60t, 64t, 65t, 121t 
- prophylaxis 64t 
Antimicrobial stewardship programme (ASP) 34, 35, 39t 
Appendectomy, surgical prophylaxis 110 
Appendicitis 53, 73t 
Arthritis, septic 69t 
Aspergillosis, invasive 64t, 65t 
Aspergillus 60 
- A. niger 66f 
Aspiration pneumonia 79t 
Azithromycin 84, 89, 92, 104t, 113, 115t, 120t 
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Azoles 59t, 61t, 62t 
Aztreonam 19t, 25, 27, 28t, 29 
B 
Bacillus species 18t 
Bacterial vaginosis 76t 
Bacteriuria, surgical prophylaxis 111t 
Bacteroides 73t, 74t, 79t 
Beta-lactam, allergy 125, 126, 130f 
Biliary sepsis 73t,  
- surgical prophylaxis 110t 
Bite wound 71t,  
- surgical prophylaxis 112t 
Blastomyces 58 
Brain abscess, see “abscess”  
Breast abscess, see “abscess” 




Campylobacter, gastroenteritis 74t, 75t 
Candida 
- C. albicans 18, 58, 60t, 65t, 66f 
- C. glabrata 58, 60t, 66f 
- C. guillermondii 60t, 66f 
- C. krusei 60t, 66f 
- C. lusitaniae 60t, 66f 
- C. parapsilosis 60t, 65t, 66f 
- C. tropicalis 60t, 65t, 66f 
Candidemia 64t, 121t 
Candidiasis 121t 
- esophageal 64t 
- invasive 64t, 65t 
Capnocytophaga spp. 71t 
Carbapenemase 26t, 28t, 29, 32f 
Carbapenems 19t, 26t, 28t, 29, 33f, 77t, 87f, 98t, 100t, 129t  
Cardiovascular infections 75t 
Caspofungin 59t, 60t, 61t, 62t, 63t, 64t, 65t 
Cat bite 71t 
Catheter-associated bloodstream infection (CASBI) 133 
- time to positivity (TTP), diagnosis 133, 134t 
Cefaclor 93, 95t 
Cefadroxil 129t 
Cefazolin 69t, 76t, 102, 107, 108, 109t, 111t, 112t, 113, 115t, 119t, 123t 
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Cefepime 20t, 25, 26t, 80t, 81t, 82t, 88, 95t, 98t, 100t, 115t, 119t, 122t, 123t 
Cefmetazole 26t 
Cefoperazone-sulbactam 20t,79t, 82t, 97t, 101t, 104t, 116t, 119t 
Cefotaxime 26t, 69t, 72t, 78t, 85, 87f, 94f, 95t, 104t, 116t, 119t, 122t, 123t 
Cefoxitin 26t, 76t 
Cefpodoxime 95t 
Ceftaroline 19t, 21 
Ceftazidime 20t, 25, 26t, 39t, 81t, 95t, 100t, 101t, 109t, 116t, 119t, 123t 
Ceftibuten 93, 95t 
Ceftriaxone 20t, 25, 26t, 69t, 72t, 74t, 75t, 79t, 80t, 81t, 82t, 95t, 104t, 108t, 116t, 119t, 
122t, 123t 
Cefuroxime 20t, 73t, 87f, 95t, 99t, 107t, 108t, 109t, 110t, 111t, 112t, 116t, 119t 
Cellulitis 22, 42, 70t 
Cephalexin 70t, 116t, 129t 
Cephalosporins 19t, 25, 28t, 33f, 71t, 93, 102t, 108t, 119t, 123t,129t, 131 
- allergy 126 
Cerebrospinal fluid (CSF) 52, 61t, 62t 
Cesarean Section, see “pregnancy” 
Chickenpox 71 
Chlamydophila pneumoniae 79t, 88 
Chlorhexidine, bath, pre-operative prophylaxis against MRSA 42, 113 
Cholangitis 53, 73t 
Cholecystitis 53, 73t, 110t 
Chronic obstructive pulmonary disease (COPD) 78t, 84, 92 
Ciprofloxacin 20t, 33f, 70t, 79t, 84, 92, 97t, 98t, 100t, 101t, 110t, 116t, 120t 
Citrobacter 26t, 28t 
Clarithromycin 84, 89, 92, 104t, 116t, 120t 
Clindamycin 19t, 23t, 70t, 71t, 76t, 77t, 79t, 102t, 104t, 107t, 116t 
Clostridium difficile 42, 43, 75t, 97t, 118t 
Cloxacillin 21, 69t, 70t, 71t, 76t, 102t, 116t, 119t 
Central nervous system (CNS) infection 72t, 122t 
Coagulase-negative staphylococci 18t, 42, 43, 47 
Colistin 27, 28t, 50, 116t 
Colitis 42, 43, 118t 
Colorectal, surgical prophylaxis 110t 
Community-acquired pneumonia (CAP) 79t, 80t, 81t, 88 - 92 
Cotrimoxazole 19t, 20t, 23t, 25, 79t, 100t, 102t, 103t 
Craniotomy, surgical prophylaxis 108t 
Cryptococcus neoformans 58, 60t, 61t 
Cystitis 51, 77t 
D 
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Daptomycin 48, 102t, 117t 
Desensitization 125 - 127 
Diabetic foot infection 49, 70t, 113 
Diloxanide 74t 
Dimorphic fungus 58, 60t 
Dog bite 71t 
Doxycycline 76t, 102t, 113, 117t 
E 
Ear, surgical prophylaxis 109 
Echinocandins 58, 59t, 65t 
Empirical therapy (ET), antimicrobial 39t, 52, 53, 67, 68, 69t – 82t, 92  
Endocarditis 38, 42, 48, 57t, 75t, 76t, 118t 
Endoscopic Retrograde Cholangio-Pancreatography (ERCP), surgical prophylaxis 110t 
Entamoeba histolytica 74t 
Enterobacter 18t, 20t, 26t, 82t 
- E. cloacae complex 28t, 98t 
Enterococcus 18t, 73t, 74t, 75t, 77t, 126 
- Enterococcus, vancomycin-resistant (VRE) 23, 24, 48 
   - Enterococcus faecalis, vancomycin-resistant (VREfs) 23, 24, 47 
- Enterococcus faecium, vancomycin-resistant (VREfm) 19, 23, 24, 47 
Ertapenem 39t, 52, 53, 117t, 119t 
Erysipelas 70t 
Erythromycin 19t, 23t, 84, 89, 92, 104t, 110t, 117t 
Enterobacteriaceae 
- ESBL-positive 19t, 51, 52 
- carbapenem-resistant (CRE) 19t, 26t, 50 
Escherichia coli 18t, 20t, 25, 27, 28t, 31t, 51, 52, 74t, 77t, 99t, 100t, 132, 134t 
Extended-spectrum beta–lactamases (ESBL) 19t, 20t, 25, 26, 27, 28t, 31f, 51, 52, 53, 82t, 
98t, 99t, 100t, 101t, 134t 
F 
Flucloxacillin 21, 117t 
Fluconazole 58, 59t, 60t, 64t, 65t, 121t 
Flucytosine 60t 
Fluoroquinolones 19t, 33f, 71t, 75t, 77t, 78t, 80t, 84, 90, 91, 92, 93, 97t, 99t, 100t, 103t, 
120t 
Fosfomycin 51, 117t 
Fracture, surgical prophylaxis 108t 
Fusarium 58, 60t 
Fusidic acid 23t, 102t 
G 
G6PD deficiency 83 
Gastric ulcer, surgical prophylaxis 109 
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Gastroenteritis 74t, 75t 
Gastrointestinal tract, upper, surgical prophylaxis 109t 
Gatifloxacin 93 
Gentamicin 20t, 23t, 33f, 55, 57t, 75t, 76t, 97t, 98t, 109t, 117t, 119t, 123t 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations 78t 
Gynaecological infections 71t, 76t 
H 
Haemodialysis 62t 
Haemophilus influenzae 18t, 47, 78t – 82t, 99t 
Head and neck infections 77t 
Hepato-Biliary System, surgical prophylaxis 110t 
Hernia Repair, surgical prophylaxis 111t, 113 
Histoplasma 58 
- H. capsulatum 60 
Hospital-acquired pneumonia (HAP) 82t 
Human immunodeficiency virus (HIV) 75t, 76t 
Hysterectomy, abdominal & vaginal, surgical prophylaxis 111t 
I 
Imipenem 20t, 30, 33f, 39t, 52, 53, 70t, 71t, 77t, 82t, 85, 88, 95t, 97t, 117t, 119t, 123t, 
129t 
Infectious mononucleosis 125 
Influenza 81t 
Intra-abdominal, infections 73t – 75t 
Itraconazole 59t, 60t, 61t, 64t, 65t, 121t 
K 
Klebsiella pneumoniae 18t, 20t, 26, 27, 28t, 51, 74t, 99t, 100t, 134t 
Known-pathogen therapy (KPT) 39t, 53, 75t, 96, 97t – 104t 
L 
Laparoscopic gall bladder surgery, surgical prophylaxis 110t 
Legionella 80t, 81t, 88 
- urinary antigen test (UAT) 132, 133t 
Levofloxacin 70t, 71t, 77t, 78t, 79t, 84, 92, 98t, 100t, 101t, 117t, 120t 
Lincomycin 126 
Linezolid 24, 39t, 47, 71t, 81t, 102t, 117t, 120t 
Liver abscess, see “abscess” 
Liver disease 49, 83 
M 
Mastectomy, surgical prophylaxis 111t, 113 
Meningitis 22, 38, 48, 52, 72t, 90, 95, 104t, 122t 
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Methicillin-resistant S. aureus (MRSA), see “Staphylococcus aureus”  
Metronidazole 42, 72t, 73t, 74t, 75t, 76t, 77t, 79t, 85, 87f, 97t, 99t, 107t, 109t, 110t, 111t, 
112t, 113, 117t, 120t, 122t 
Micafungin 59t, 60t, 62t, 63t, 64t, 65t, 121t 
Minocycline 23t, 117t 
Monobactam 19t, 29 
Moraxella catarrhalis 18t, 47, 78t, 79t, 82t, 93, 99t 
Moxifloxacin 71t, 84, 93, 118, 120t 
Mucormycosis 61t 
Mupirocin, nasal, pre-operative prophylaxis against MRSA 42, 113 
Mycobacteria 47 





- carriage, MRSA 42 
- surgical prophylaxis 109t, 113 
Neck, infection 77t 
Necrotizing fasciitis 23t, 70t, 71t, 83 
Neisseria 
- N. gonorrhoeae, 69t, 76t 
- N. meningitides, meningitis 72t 
Neomycin 110t 
Netilmicin 55, 118t, 119t, 123t 
Neurosurgery, surgical prophylaxis 108t 
Neutropenic fever 38, 43, 52, 64t, 65t, 118 
New Delhi metallo-beta-lactamase 1 (NDM-1) 27, 28t 
Nitrofurantoin 20t, 77t, 100t 
O 
Odontogenic, infection 77t 
Oral-pharyngeal, surgical prophylaxis 109t 
Orthopaedic & traumatology, surgical prophylaxis 108t 
Oseltamivir 81t 





Pancreatitis 85, 86, 87f 
Pasteurella multocida 71t 
Pelvic inflammatory disease 76t 
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Penicillin 19t, 21, 25, 33f, 70t, 77t, 78t, 79t, 81t, 82t, 91, 92, 93, 94f, 95t 
- allergy 71t, 78t, 79t, 82t, 101t, 102t, 104t, 125, 126, 129t, 131 
- penicillin G 71t, 78t, 93, 95t, 104t, 108t, 118t, 122t, 126 
- penicillin V 71t, 93, 95t 
Penicillium marneffei 60t 
Peritoneal dialysis 43 
Peritonitis  
- secondary 53, 73t 
- continuous ambulatory peritoneal dialysis (CAPD) 123, 135 
Piperacillin 20t, 85, 93, 95t, 101t, 118t, 119t 
Piperacillin-tazobactam 20t, 33f, 70t, 77t, 79t, 80t, 81t, 82t, 87f, 88, 93, 99t, 100t, 101t, 
118t, 119t 
Posaconazole 60t, 61t, 64t, 65t, 121t 
Pregnancy 57 
- abortion, surgical prophylaxis, 111t, 113 
- cesarean section, surgical prophylaxis 111t 
Prophylaxis, antimicrobial 42, 43, 64t, 85  
- surgical 105, 106, 107t – 112t, 113 
Prosthesis, surgical prophylaxis 
- heart valve 107 
- joint 108 
Prosthetic joint, infection 135  
Proteus mirabilis 18t 
Pseudallescheria 60 





Ranson's criteria, severity assessment of pancreatitis 86t 
Respiratory tract, infections 40, 78t – 82t 
Rifampin 122t 
Ruptured viscus, surgical prophylaxis 112t 
S 
Salmonella 26, 69t, 74t, 75t 
Sepsis 23t, 73t 
Serratia 26 
Skin 22, 42, 53 
- infections, skin and soft tissue 23t, 48, 49, 70t, 81t, 83 
- testing, penicillin allergy 125, 126, 131 
Staphylococcus aureus 18, 24, 69t, 70t, 71t, 74t, 76t, 79t, 82t, 93, 102t, 132, 133t, 134t 
- Staphylococcus aureus, methicillin-resistant (MRSA) 19t, 21, 22, 23t, 42, 43, 44, 
47, 48, 49, 69t, 81t, 82t, 102t, 113, 122, 126, 134t 
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- Staphylococcus aureus, methicillin-resistant, community-associated (CA-MRSA) 
21, 22, 23, 42, 81t, 102t 
- Staphylococcus aureus, methicillin-resistant, healthcare-associated (HA-MRSA) 
21, 22, 23 
Stenotrophomonas maltophilia 20t, 49, 103t  
Stevens-Johnson syndrome 42, 125 
Streptococcus 69t, 70t, 71t 
- Group A, S. pyogenes, necrotizing fasciitis 83 
- Group B, 18t, 72t, 77t 
- S. milleri 74t, 79t 
- S. pneumoniae 72t, 78t, 79t, 81t, 82t, 84, 88, 90, 92, 93, 94f, 95t, 104, 122, 132, 
133, 134t 
- S. pneumoniae, drug-resistant (DRSP) 88, 90 
- S. suis, meningitis 72t 
- S. viridians, endocarditis 75t 
Switch therapy, I.V. to P.O. 38, 39t 
T 
Teicoplanin 39t, 118t 
Thoracic, surgical prophylaxis 107t 
Thyroid & parathyroid glands, surgical prophylaxis 108t 
Ticarcillin 20t, 93, 95t 
Ticarcillin-clavulanate 20t, 33f, 73t, 79t, 80t, 81t, 82t, 101t, 103t, 118t, 119t 
Tigecycline 27, 28t, 49, 118t 
Tobramycin 55, 57, 118t, 119t, 123t 
Toxic shock syndrome 71t 
- streptococcal, 71t, 83 
Traumatic wound, surgical prophylaxis 112t 
Trichosporon 58, 60t 
Tricuspid valve, endocarditis 76t 
Tuberculosis, see “Mycobacterium tuberculosis” 
U 
Urinary tract, infection 25, 27, 77t, 98t, 100t 
Urology, surgical prophylaxis 111t 
Urticaria, penicillin allergy 125 
V 
Vancomycin 19t, 21, 23, 24, 39, 42, 43, 44, 45, 46, 47, 48, 55, 69t, 72t, 81t, 82t, 90, 97t, 
102t, 107t, 113, 118t, 120t, 122t, 125, 126 
Ventriculo-peritoneal (V-P) shunt, surgical prophylaxis 108t 
Vibrio vulnificus, necrotizing fasciitis 71t 
Voriconazole 59t, 60t, 61t, 63t, 64t, 65t, 121t 
W 
Wound, infection 42, 113 
Y  
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Zygomycetes 58, 60t 
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